

Semen Levels of Spermatid-Specific Thioredoxin-3 Correlate with Pregnancy Rates in ART Couples

Clayton Buckman^{1,2,9}, Christophe Ozanon^{5,9}, Jing Qiu³, Miriam Sutovsky^{1,2}, Joyce Ann Carafa^{4†}, Vanesa Y. Rawe⁶, Gaurishankar Manandhar¹, Antonio Miranda-Vizuetes^{7¶}, Peter Sutovsky^{1,2¶*}

1 Division of Animal Sciences, University of Missouri, Columbia, Missouri, United States of America, **2** Departments of Obstetrics, Gynecology & Women's Health, School of Medicine, University of Missouri, Columbia, Missouri, United States of America, **3** Department of Statistics, University of Missouri, Columbia, Missouri, United States of America, **4** Cell and Immunology Core, University of Missouri, Columbia, Missouri, United States of America, **5** Assisted Fertilization Medical Center NATECIA, NOVESCIA Laboratory, Clinique NATECIA, Lyon, France, **6** REPROTEC, Buenos Aires, Argentina, **7** Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain

Abstract

Spermatid specific thioredoxin-3 (SPTRX3 or TXNDC8) is a testis/male germ line specific member of thioredoxin family that accumulates in the superfluous cytoplasm of defective human spermatozoa. We hypothesized that semen levels of SPTRX3 are reflective of treatment outcome in assisted reproductive therapy (ART) couples treated by *in vitro* fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Relationship between SPTRX3 and treatment outcome was investigated in 239 couples undergoing ART at an infertility clinic. Sperm content of SPTRX3 was evaluated by flow cytometry and epifluorescence microscopy, and correlated with clinical semen analysis parameters, and data on embryo development and pregnancy establishment. High SPTRX3 levels (>15% SPTRX3-positive spermatozoa) were found in 51% of male infertility patients (n = 72), in 20% of men from couples with unexplained, idiopathic infertility (n = 61) and in 14% of men from couples previously diagnosed with female-only infertility (n = 85). Couples with high SPTRX3 produced fewer two-pronuclear zygotes and had a reduced pregnancy rate (19.2% pregnant with >15% SPTRX3-positive spermatozoa vs. 41.2% pregnant with <5% SPTRX3-positive sperm; one-sided p < 0.05). The average pregnancy rate of all 239 couples was 25.1%. Live birth rate was 19.2% and lowest average SPTRX3 levels were found in couples that delivered twins. Men with >15% of SPTRX3-positive spermatozoa, a cutoff value established by ROC analysis, had their chance of fathering children by IVF or ICSI reduced by nearly two-thirds. The percentage of SPTRX3-positive spermatozoa had predictive value for pregnancy after ART. Gradient purification and sperm swim-up failed to remove all SPTRX3-positive spermatozoa from semen prepared for ART. In summary, the elevated semen content of SPTRX3 in men from ART couples coincided with reduced incidence of pregnancy by IVF or ICSI, identifying SPTRX3 as a candidate biomarker reflective of ART outcome.

Citation: Buckman C, Ozanon C, Qiu J, Sutovsky M, Carafa JA, et al. (2013) Semen Levels of Spermatid-Specific Thioredoxin-3 Correlate with Pregnancy Rates in ART Couples. PLoS ONE 8(5): e61000. doi:10.1371/journal.pone.0061000

Editor: Joel R. Drevet, Clermont-Ferrand Univ., France

Received: December 10, 2012; **Accepted:** March 5, 2013; **Published:** May 29, 2013

Copyright: © 2013 Buckman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was funded by grant number 1R21HD066333-01A1 from the National Institutes of Health, NICHD, grant number CB000414 from the Research Board of the University of Missouri, seed funding from the Food for the 21st Century Program of the University of Missouri and Undergraduate Summer Research Internship, College of Agriculture, Food and Natural Resources (CAFNR), University of Missouri. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Dr. Vanesa Rawe is employed by a commercial company, REPROTEC, Buenos Aires, ARGENTINA. The authors further declare that this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: SutovskyP@missouri.edu

9 These authors contributed equally to this work.

¶ These authors also contributed equally to this work.

† Deceased.

Introduction

Infertility and the pursuant assisted reproductive therapies (ART) are on rise worldwide. At the same time, oocyte/embryo culture and manipulation technologies, and the diagnostic techniques for female infertility have been advancing steadily. On the contrary, the andrological aspect of infertile couple evaluation still relies mostly on traditional, microscopy based semen analysis, in addition to clinical examinations, hormonal profiles, and cytogenetic and Yq microdeletion profiles. To some extent, the assessment of the DNA fragmentation or chromatin damage, associated with oxidative stress, apoptosis, or male genital tract infection are used as diagnostic tools. Exposure to xenobiotics and advanced paternal age are possible risk factors associated with

infertility. Sperm parameters can be measured in specialized laboratories by the DNA-integrity based assays such as SCSA [1], Comet [2] and TUNEL [3], but the value of such exploration is uncertain for the moment [4]. As the repertoire of flow cytometric semen evaluation methods increases, the challenge is on to find new tools and fertility markers to reliably diagnose human male infertility [5]. In addition to DNA fragmentation-based methods, mitochondrial membrane potential probes [6], lectins [7], viability stains [8], apoptosis-detecting probes [9], and antibodies against proteins present predominantly in normal or defective spermatozoa are being adapted for flow cytometric semen analysis (reviewed in [10]).

Thioredoxins (TRX) are a class of redox proteins that function as general protein oxidoreductases by the reversible oxidation of

the cysteine residues of their active site whose conserved sequence is Cys-Gly-Pro-Cys. Thioredoxins are maintained in their reduced active form by the flavoprotein thioredoxin reductase (TRXR) at the expense of the reducing power of NADPH [11]. The functions of thioredoxins are typically wide, mostly relying on their redox capabilities, including antioxidant defense, modulation of cell growth and differentiation, regulation of apoptosis and activation of membrane ion channels, among others [11,12].

Besides ubiquitous thioredoxins found both in cytoplasm and mitochondrial matrix in all cell types, mammals are equipped with an additional set of thioredoxins with an expression pattern restricted to male germ cells [13]. One of such thioredoxins is Spermatid-Specific Thioredoxin 3 [SPTRX3; HUGO nomenclature-TXNDC8 (thioredoxin domain containing 8)]. This thioredoxin is initially observed in the Golgi apparatus of pachytene spermatocytes; it is later retained post-meiotically in round spermatids in close association with the developing acrosomal granule, suggesting a function in acrosomal biogenesis [14]. Once the acrosome is formed, the residual SPTRX3 accumulates in the cytoplasmic lobe of the elongating spermatids ready to be discharged in the form of residual bodies. Interestingly, SPTRX3 remains undetectable in fully differentiated normal spermatozoa of various animal species, but is retained in the superfluous cytoplasm found filling the nuclear vacuoles and wrapping around the sperm tail midpieces in morphologically aberrant human spermatozoa [14,15]. A dual flow cytometric trial revealed a robust positive correlation between sperm levels of SPTRX3 and ubiquitin (a validated defective sperm biomarker [16]) in a cohort of 19 infertile and 5 fertile subjects [14]. A subsequent study used ImageStream technology combining flow cytometry and light microscopy, to directly demonstrate that the flow cytometric events with high SPTRX3 induced fluorescence are defective spermatozoa with excess cytoplasm and/or nuclear vacuoles [15].

In addition to spermatid specific thioredoxins 1, 2 and 3 [14,17,18,19], the residual cytoplasm carries cytoplasmic enzymes such as glucose-6-phosphate dehydrogenase [20], superoxide dismutase [21], lactic acid dehydrogenase [22] and creatine phosphokinase [20,23]. Retention of residual cytoplasm coincides with impaired sperm function in humans [24,25]. In most mammals, the last remnant of spermatid cytoplasm is rejected in the form of a cytoplasmic droplet (CD). Human spermatozoa are unique in that they do not develop a typical CD. The superfluous, redundant cytoplasm (or “excess residual cytoplasm” [26]) in human spermatozoa is an altogether different structure, as it may not be rejected by the spermatozoon in a CD-like manner. It coincides with increased content of reactive oxygen species (ROS) in semen, which at high concentrations are cytotoxic [27]. The ROS generated by excess sperm cytoplasm, or at least by some types of it, can inflict damage by oxidation of unsaturated fatty acids in the sperm plasma membrane, and by DNA breakage, causing reduced motility, pregnancy loss, and embryo morbidity [28].

We conducted the present study to determine the value of the SPTRX3 as a predictor of ART treatment outcome, setting the stage for the validation of SPTRX3 as a biomarker of human male infertility. Our hypothesis was that infertile men will have a significantly higher content of SPTRX3 present in their sperm samples, compared to fertile males. We examined men from 239 couples undergoing infertility treatment because of previously diagnosed female, male, combined (male and female) or idiopathic infertility. We were particularly interested in assessing possible effect of high semen SPTRX3 levels on pregnancy rates.

Results

High Flow Cytometric SPTRX3 Values Coincide with Low Pregnancy Rates after ART

Sperm content of SPTRX3 was evaluated by flow cytometry and correlated with pregnancy rates in 239 couples treated by IVF and/or ICSI. The division of flow cytometric histograms into markers M1-M3 (**Figure 1**) allowed us to distinguish between cellular debris (M1), cells not carrying detectable SPTRX3, with only a background-level of fluorescence (M2) and SPTRX3-positive, defective spermatozoa (M3). The average % of SPTRX3-positive cells (%M3) for the whole cohort of 239 couples was 14.3%. The average pregnancy rate for all 239 couples enrolled in this study was 25.1%. It was 29.8% for ICSI treated couples (n = 131) and 19.4% for IVF couples (n = 108). Average pregnancy rate for couples above the average %M3 level (n = 83) was 20.5%. Average pregnancy rate for couples below the average %M3 (n = 156) was 27.6%. The median %M3 value, i.e. the value of %M3 at which half the subjects had higher and half had lower SPTRX3 levels, was 12.01%. Average pregnancy rate for couples above the median was 20.2%. Average pregnancy rate for couples below the median was 30.3%, which was significantly higher than the average pregnancy rates of the above-median group (p = 0.04).

The dosage effect of SPTRX3 on pregnancy rates was captured when all 239 couples were divided into four groups based on %M3-SPTRX3 values (less than 5% SPTRX3-positive spermatozoa; 5–9.99% positive spermatozoa, 10–14.99% positive spermatozoa; 15% or more SPTRX3-positive spermatozoa). In this partition, the percentage of pregnant couples decreased progressively with the increased SPTRX3 values (**Figure 2A**). The likelihood of pregnancy was further reduced if only the high SPTRX3 men from idiopathic couples, were analyzed (**Figure 2A**; last column). Average pregnancy rate of this group (n = 12) was only 16.7%. Compared to men with less than 5% SPTRX3-positive spermatozoa, those carrying more than 15% of such cells had their chance of conceiving reduced by a half (41.2% pregnant, vs. 19.2% pregnant; one-sided p < 0.05). The ROC analysis revealed that the cutoff values of 12.5% and 15% had a good balance of test sensitivity and specificity (see **Table S1 in File S1**). The average pregnancy rate in couples treated by ICSI and having >15% SPTRX3-positive spermatozoa (n = 60) was 36.7%. Average pregnancy rate was only 11.1% in IVF couples with >15% positive spermatozoa (n = 18). The IVF couples with <15% SPTRX3-positive spermatozoa (n = 90) achieved a pregnancy rate of 21.1%.

Discriminant analysis revealed that %M2 SPTRX3 was a significant positive predictor of pregnancy in IVF couples and the median M3 was a significant negative predictor for the ICSI group (see **Supplemental Statistics – Section ANALYSIS I & Table S11 in File S1**). Based on clinical indication, SPTRX3 levels (%M3) were significantly higher (p < 0.05) in couples with male and combined (male and female) infertility, compared to couples with female-only or idiopathic infertility (**Figure 2B**). Also, SPTRX3 levels were significantly higher (p < 0.001) in ICSI couples compared to IVF couples (**Figure 2C**). Within the ICSI-treated group, couples that achieved pregnancy had numerically higher %SPTRX3 positive spermatozoa, but this increase was not statistically significant. The levels of sperm SPTRX3 were not significantly different between smokers and non-smokers when all couples were evaluated (**Figure S2**). Pregnancy outcomes were confirmed in 57/60 pregnant couples; 46 of those couples delivered babies (confirmed live birth rate of 19.2%) (**Table S2A in File S1**).




Figure 1. Examples of flow cytometric histograms (A, B) and corresponding light scatter diagrams (A', B') of two male patients with varied SPTRX3 levels. Histograms, representative of SPTRX3 fluorescence levels in 10,000 cells/sample are divided into marker areas M1 (low fluorescent spermatozoa, sperm fragments and cellular debris), M2 (mostly intact spermatozoa with background-level fluorescence) and M3 (defective, SPTRX3-positive spermatozoa and immature sperm forms with high fluorescence). Percentage of SPTRX3-positive spermatozoa out of total sperm content, including markers M1, M2, and M3 is shown. Gate R1 in scatter diagrams of visible light separates spermatozoa (each dot is one cell) from other flow cytometric events; resultant percentage is percent of high/low fluorescent spermatozoa from total number of flow cytometric events measured per sample in order to acquire 10,000 measurements. Sample B was donated by a patient previously diagnosed with male infertility (oligo-astheno-teratozoospermia; 5 million sperm/ml, 30% motility, 22% normal morphology). Flat histogram-curve and a secondary peak within marker area M3 coincide with 25.9% of SPTRX3-positive spermatozoa in this sample. Sample A was donated by a presumably fertile man with acceptable clinical semen parameters (80 million/ml, 50% motility, 74% normal morphology) whose female partner suffered from endometriosis. doi:10.1371/journal.pone.0061000.g001

Lowest average SPTRX3 levels were found in couples that delivered twins ($n = 12$; **Figure 2E**; **Table S2B in File S1**), compared to those delivering a singleton ($n = 34$) and those that miscarried ($n = 10$). In addition to pregnancy and live birth rates, parameters of embryo development and numbers of oocytes and embryos produced per couple were analyzed. Numerically, couples in which men had less than 5% of SPTRX3 positive spermatozoa produced most normal two-pronuclear zygotes and transferable embryos (**Table S3 in File S1**). However, no significant correlations were found between parameters of early embryo development and flow cytometric SPTRX3 levels.

Flow Cytometric SPTRX3 Levels Reflect Clinicians' Treatment Decision, and Reveal Undiagnosed Male Infertility in Idiopathic Infertility Cases

The SPTRX3 levels in all 239 couples were compared based on pregnancy outcome and clinical indication (**Figure 2D**). Compared to female infertility couples, the average %M3 value of SPTRX3 in diagnosed male infertility cases was increased by 63%. Elevated SPTRX3 levels (>15% M3) coincided with the clinician's decision to treat by ICSI. Consequently, logistic regression and discriminant function analysis were used to determine the relationship between treatment assignment (ICSI or IVF) and semen SPTRX3 levels (**Table S4 in File S1**; **Supplemental Statistics**, section **ANALYSIS II & Table S12, S13 in File S1**). Among 16 flow-cytometric parameters, only median M2, Mean M2 and %M1 were not significant for predicting the treatment assignment. Mean M1 and Median M1 had the largest influence on the odds of being assigned to IVF treatment. The odds of being assigned to IVF treatment

increased by over 34 fold and 4 fold for every unit of increase in Mean M1 and Median M1, respectively. However, we noticed that the ranges of Mean M1 and Median M1 were small (their values varied between 1 and 4). The next three most influential predictors were CV M1, %M2 and %M3. For every unit increase in CV M1 and %M3, the odds of being assigned to FIV treatment decreased by 16.3% and 9.6%, respectively. For every unit increases in %M2, the odds increased by 14.1%. Discriminant analysis identified %M2 SPTRX3 as a positive discriminant for IVF assignment and Mean M3, Median M3 and % M3 SPTRX3 as positive discriminants for ICSI assignment. Thus, increased SPTRX3 content in spermatozoa can be used as an indication for ICSI treatment. Among the six conventional semen parameters, only sperm volume was not significant predictor for treatment assignment (**Table S4 in File S1**). Motility parameters, PR and M gave the most explanatory powers with odds ratio of 1.176 and 1.142 (i.e. the odds of being assigned to IVF treatment increases 17.6% and 14.2% for every unit increase in PR and Mob measurements, respectively).

Flow Cytometric SPTRX3 Values Reflect Sperm SPTRX3 Retention Phenotypes Observed by Epifluorescence Microscopy

Immunofluorescence processing and subsequent analysis of a subset of 150 samples by epifluorescence microscopy identified varied phenotypes of SPTRX3-retention by defective spermatozoa, ranging from spermatozoa bearing a small dot of SPTRX3 (**Figure 3A, 3E**) to the highly SPTRX3-positive spermatozoa (**Figure 3A, 3G**) and SPTRX3-containing cellular debris (**Figure 3F**), readily obvious even at low magnification (compare




Figure 2. Diagrams of average SPTRX3 content in spermatozoa of men from 239 infertile couples. (A) Average pregnancy rates after infertility treatment (IVF or ICSI) decreased gradually with the increased sperm SPTRX3-content in 239 couples divided by % of SPTRX3 spermatozoa (flow cytometric %M3 value; x-axis) into subgroups with less than 5%, 5–9.99%, 10–14.99%, and more than 15% of SPTRX3-positive spermatozoa. Compared to men with less than 5% SPTRX3-positive spermatozoa, those carrying more than 15% of such cells had their chance of conceiving reduced by a half (41.2% pregnant, vs. 19.2% pregnant; one-sided $p < 0.05$). **(B)** Low levels of sperm SPTRX3 were found in female and idiopathic

infertility-couples, compared to male I an combined male & female infertility-couples. Different superscripts mark statistically significant differences between columns at $p < 0.001$. The most significant difference was observed between female and male infertility couples ($p < 0.001$). (C) Couples treated by IVF had significantly lower average SPTRX3-levels than those treated by ICSI, regardless of whether or not they achieved a pregnancy. Superscripts ^{a, b} mark statistical difference at $p < 0.05$. The most significant difference was found between pregnant IVF couples and pregnant ICSI couples ($p < 0.001$). (D) Couples with female and idiopathic infertility had significantly lower SPTRX3 levels (average %M3-values) than couples previously diagnosed with male or combined (male and female) infertility. (E) Distribution of SPTRX3 levels within cutoffs in patients divided based on pregnancy outcome. Note that the couples delivering twins had the highest percentage of men with %M3 SPTRX below 15% and lowest percentage of men with $>15\%$ M3 SPTRX3.
doi:10.1371/journal.pone.0061000.g002

Figure 3C to Figure 3B). Similar labeling was obtained in spermatozoa immunolabeled without fixation (**Figure 3H**). Some SPTRX3 positive spermatozoa persisted in semen samples purified by gradient centrifugation and swim-up (**Figure 3 I–K**). Non-sperm elements/bodies present in the analyzed samples did not display detectable SPTRX3 fluorescence. The epifluorescence microscopy-analysis of SPTRX3 correlated with flow cytometric evaluation of this subset of 150 patients and was reflective of pregnancy rates (**Figure S3 in File S1; Table S5A, S5B in File S1**).

Effect of High SPTRX3 Content on Pregnancy Rates after Adjustment for Partners' Age

Female patients above 35 years of age tend to produce fewer oocytes after superovulation, and these oocytes are perceived to be of lesser quality and developmental potential. It was thus useful to assess whether high semen content of SPTRX3 in male partners of female patients 35 years or older could further aggravate couples' infertility. When the couples were divided based on female age and male content of SPTRX3 (**Table S6 in File S1**), and by age and indication (**Table S7 in File S1**), there was a non-significant trend towards higher pregnancy rates in low SPTRX3 couples




Figure 3. Epifluorescence microscopy of sperm samples processed for flow cytometric measurements of SPTRX3 (red). The DNA-stain DAPI (blue) was added after flow cytometric analysis. Epifluorescence images are superimposed onto parafocal differential interference contrast (DIC) images (gray). (A) Examples of SPTRX3 labeling in samples from male infertility patients. Arrowheads point to minor carryovers of residual cytoplasm in spermatozoa and immature sperm forms; some of these cytoplasmic structures may not be detectable by conventional transmitted light microscopy, but can be identified accurately by SPTRX3 labeling. (B, C) The difference in SPTRX3 content is obvious even at low magnification between a sample from a presumed fertile donor (B) and the one of a patient previously diagnosed with oligo-astheno-teratozoospermia (C). (D–G) High magnification renderings of various patterns of SPTRX3 retention in defective spermatozoa, including a predominant sperm head/nuclear labeling (D), minor SPTRX3 retention in the sperm head (E; arrows) and sperm tail connecting piece (E; arrowhead), sperm-derived cellular debris free of DNA/chromatin (F), immature, spermatid-like form (G; top), and SPTRX3-filled large nuclear vacuole (G; bottom). (H) Immunolabeling of SPTRX3 in a frozen-thawed semen sample labeled according to a simplified protocol omitting sperm fixation and washing. (I–K) Detection of SPTRX3 before (I) and after semen purification on PureSperm gradient (J), and in a sample purified by swim-up after PureSperm treatment (K). Defective spermatozoa are not removed completely by this two-step procedure. Scale bars are 10 μm in all panels except B, C, where they represent 20 μm .
doi:10.1371/journal.pone.0061000.g003

regardless of female age. Male age itself did not show correlation with pregnancy rates, SPTRX3 levels or conventional semen parameters. There was a moderate-to-high correlation between flow cytometric data and several parameters of conventional, clinical semen analysis (**Table S8 in File S1**).

Next, the logistic regression analysis was applied to test the relationship of pregnancy rate with the sperm quality parameters, taking into consideration of female age and treatment assignments (**Supplemental Statistics – ANALYSIS III in File S1**). Considering only the patients assigned to IVF treatment, both %M2 and %M3 SPTRX3 were significant predictors of pregnancy rate, with or without adjustment for the female age factor. Importantly, none of the conventional semen parameters, or other remaining 14 flow cytometric SPTRX3 parameters, was significant even with adjustment for the female age. The odds of getting pregnant in the IVF group were significantly reduced by increased %M3 value, with ($p < 0.05$) or without ($p < 0.05$) adjustment for maternal age. The %M2 was also a significant predictor for pregnancy rate for IVF group ($p < 0.02/p < 0.05$ with/without age adjustment).

For the ICSI group, the pregnancy rate was not affected by any of the flow cytometric or conventional sperm quality parameters or the female age factors. This is not surprising since ICSI can overcome a wide range of sperm anomalies that would hinder conventional IVF treatment. When considering all patients together, %M2 and %M3 SPTRX3 were not significant predictors for pregnancy rate ($p > 0.1$). However, when we categorized the %M3 levels into four groups (below 5%, between 5–10%, between 10–15%, above 15%), the estimated odds ratio between the below 5% group and the above 15% group had a p -value = 0.06. After adjusting for female age above/below 35 years, the adjusted odds ratio for the <5% SPTRX3 group over the >15% SPTRX3 group had a $p < 0.05$. Using 85% as a cutoff for %M2 (normal spermatozoa), the below 85% group and above 85% group had significantly different pregnancy rates when considering all patients together. The odds of getting pregnant for the >85% %M2 group were significantly higher than that for the <85% group ($p < 0.05$) and the pregnancy rate was 41.6% versus 22.72%. After the adjustment for the female age above 35, the odds ratio remained significant ($p < 0.05$).

Relationship between Flow Cytometric SPTRX3 Parameters, Clinical Semen Parameters and Clinical Diagnosis of Male Infertility

This analysis was performed using logistic regression analysis (*SAS proc log*) of SPTRX3 parameters and conventional semen parameters including sperm concentration (C), semen volume (V), % normal spermatozoa (NX), progressive motility (PR), % motile (M) and % necrotic (NEC) (**Table 1**). All parameters except V were significant predictors for the clinical diagnosis of male infertility (**Table 2**). NX, PR, M and C were negative predictors for male infertility. Among 16 flow cytometric parameters (**Table 2**), Mean M1, Median M1, CV M1, %M2 and %M3 were the most sensitive predictors for male infertility. Discriminant function analysis identified PR, M, NX, C, %Total and %M2 SPTRX3 as the discriminants correlated positively with sperm quality (**Supplemental Statistics – Section ANALYSIS IV, Table S14, S15 in File S1**). Negative discriminants included %M3, Mean M3 and Median M3 SPTRX3. Analysis based on etiology/testiculopathy (**Table 3**) revealed highest levels of SPTRX3 in men from male infertility couples ($n = 72$) diagnosed with oligo-asthenozoospermia. Couples with astheno-teratospermia had the lowest SPTRX3 and highest pregnancy rates. Altogether, 97.2% of male-only infertility couples were treated

by ICSI. Spearman rank correlation was used to confirm the relationship between sperm SPTRX3 values and conventional semen parameters. Five most informative flow cytometric SPTRX3 parameters (Mean M1, Median M1, CV M1, %M2, %M3) were significantly correlated with conventional semen parameters, particularly with motility parameters M and PR (**Table S9 in File S1**). The %M3 parameter, capturing cells with high SPTRX3 content, also correlated negatively with % normal spermatozoa (NX) and sperm count (C), and positively with % necrotic spermatozoa (NEC).

Discussion

Present statistical analyses indicate that high semen content of SPTRX3 in infertile men translates into a reduced chance of impregnating their female partners via ART. In fact, couples' pregnancy rates were significantly lower for men with >15% SPTRX3 sperm compared to men with <5% SPTRX3 cells. Since the treatment decision/assignment in the examined 239 cases was in part based on semen analysis, it is no surprise that men from IVF couples had significantly lower average SPTRX3 levels than men from couples that were treated by ICSI. That the increased levels of SPTRX3-positive spermatozoa predispose couples for ICSI treatment is obvious in spite of the fact that several couples were initially treated by IVF, without success, before the ICSI treatment was applied. Altogether, pregnancy rates fell progressively with increasing semen SPTRX3 levels.

When broken down into ICSI and IVF groups, couples divided by %M3 SPTRX3 showed high pregnancy rates in ICSI group with <5 %M3. On average, ICSI and male infertility cases had significantly higher %M3 values but also slightly higher pregnancy rates than IVF and female-only infertility cases. This is understandable because most of these cases were oligo-asthenoteratozoospermic and therefore treated by ICSI. The IVF patients had overwhelmingly female-only infertility, with poor oocyte quality being the likely contributor to a high incidence of failed IVF treatment (75%). However, this could also have been compounded by undiagnosed male infertility, indicated by high SPTRX3 levels in 20% of those presumed female-only infertility couples. Consequently, the percentage of mature oocytes that formed two pronuclei after assisted fertilization decreased in a stepwise manner, in parallel with increasing %M3 SPTRX3 in both the IVF-treated and ICSI-treated couples. Altogether, high sperm SPTRX3 levels seem to coincide with clinical decision to treat by ICSI. The SPTRX3-levels corroborate previous clinical diagnosis of male infertility, and reveal undiagnosed male infertility in a fraction of cases with idiopathic and female-only infertility.

While the majority of the 239 couples in this study were assigned to IVF or ICSI based on their clinical test results, our SPTRX3 results indicate that approximately 20% of IVF couples would have profited from ICSI because of undiagnosed male infertility. **Table S3 in File S1** shows that sperm SPTRX3-levels but not couples' clinical diagnosis, in part based on subjective semen analysis, coincided with successful fertilization and formation of two normal pronuclei in the resultant zygotes. While couples with <5 %M3 values of SPTRX3 produced 2-PN zygotes in 86.2% of fertilized oocytes, idiopathic couples with >15 %M3 did so in only 69.7% of oocytes (see **Table S3A in File S1**; column 9). No such differences were observed based on clinical diagnosis/indication (**Table S3B in File S1**). There was no significant difference in %M3 values of SPTRX3 between female and idiopathic cases. However, 20% of the idiopathic cases showed high SPTRX3 values (>15% M3), indicating that these

Table 1. Average clinical semen parameters in 239 male patients divided by %M3 SPTRX3 and pregnancy.

%M3 SPTRX3	N	% pregnant	Semen volume	Sperm concentration	% dead spermatozoa	% motile spermatozoa	% progressively motile spermatozoa	% normal spermatozoa
<5%	16	41.2%	Mean	95.2	22	49	28	48
			SE	21.3	2	2	3	4
5-9.99%	57	29.8%	Mean	83.6	27	46	27	46
			SE	7.1	1	1	1	2
10-14.99%	88	23.9%	Mean	71.1	28	42	24	42
			SE	5.0	1	1	1	2
>15%	78	19.2%	Mean	40.6	33	33	16	35
			SE	5.2	2	2	1	2
>15% idiopathic	12	16.7%	Mean	64.0	30	44	24	45
			SE	18.4	4	2	2	4
Pregnant	60	100%	Mean	65.8	29	38	20	38
			SE	7.5	1	2	1	2
Non-pregnant	179	0%	Mean	65.8	29	41	23	43
			SE	4.0	1	1	1	1

The only group that shows somewhat reduced average clinical semen parameters are the men with highest SPTRX3 levels (>15% M3). Idiopathic infertility patients with apparently high SPTRX3 level (>15% idiopathic; bottom row) shows acceptable, normal clinical semen parameters. David's classification scheme for sperm morphology was employed [32,33]. SE = standard error. doi:10.1371/journal.pone.0061000.t001

Table 2. Relationship between the clinically diagnosed male infertility and individual, conventional and flow cytometric SPTRX3 parameters reflective of sperm quality.

Parameter	p-value	Odds ratio*
V	0.9833	NA
PR	<0.0001	0.677
NX	<0.0001	0.903
NEC	<0.0001	1.07
M	<0.0001	0.772
C	<0.0001	0.948
Median ALL	0.0007	1.055
Median M3	<0.0001	1.028
Median M2	0.0176	1.074
Median M1	<0.0001	0.08
Mean all	<0.0001	1.055
Mean M3	<0.0001	1.022
Mean M2	0.0249	1.084
Mean M1	<0.0001	0.014
Total	<0.0001	0.915
%M3	<0.0001	1.12
%M2	<0.0001	0.869
%M1	0.8212	NA
CVALL	0.0005	1.007
CVM3	0.0131	1.012
CVM2	0.3455	NA
CVM1	<0.0001	1.241

An odds ratio smaller than 1 indicates that the parameter is negatively associated with the odds of being diagnosed with male infertility. A larger than 1 odds ratio indicates a positive relationship between the parameter and the clinical diagnosis of male infertility. An odds ratio larger than 1, e.g. 1.12 is interpreted as "the odds of being diagnosed with male infertility increase by 12% for every unit of increase in the parameter measurements." An odds ratio smaller than 1, e.g., 0.014, is interpreted as "the odds of being diagnosed with male infertility decrease by 98.6% for every unit of increase in the measured parameter." Abbreviations: C = sperm count; V = semen volume; M = total motility; PR = progressive motility; NX = morphology/% normal spermatozoa; NEC = percent of necrotic spermatozoa assessed by Williams test. doi:10.1371/journal.pone.0061000.t002

were in fact male infertility cases. Similarly, 20% of presumed fertile males in couples diagnosed with female-only infertility also had >15% SPTRX3-positive spermatozoa. Together with the effect of SPTRX3 on pregnancy rates, these data illustrate the predictive value of SPTRX3-based semen analysis for treatment outcome.

Table 2 and **Table S8 in File S1** reveal relationship between clinically diagnosed male infertility and SPTRX3 parameters. Furthermore, **Table 1** shows that men with high SPTRX3 levels show acceptable clinical semen parameters, but low pregnancy rates are achieved by their female partners. As shown in **Table S8 in File S1**, the levels of correlation (r-values) between flow cytometric parameters (%M3; %TOTAL, GeoMean M3) and conventional semen parameters are varied, depending on how the patient pool was subdivided based on indication, treatment decision and treatment outcome. All three flow cytometric parameters show median level of correlation with some clinical semen parameters in some subgroup but not in others. This indicates that sperm SPTRX3 values are relatively independent of conventional semen parameters. The flow cytometric parameter

most closely correlated with clinical semen parameters is the %TOTAL, which reflects the percentage of flow cytometer-registered events corresponding to intact spermatozoa (both morphologically normal and abnormal) out of all objects passing through a flow cytometer, including sperm fragments and debris present in semen sample. This is based on visible light scatter of registered events rather than on SPTRX3-induced fluorescence. The proposition of a sperm quality test that is relatively independent of conventional semen parameters but predictive of pregnancy outcome arrives at a time of renewed calls for more accurate semen analysis. Some recent studies even go as far as implying that even the strictest, most accurate morphological criteria could lead to diagnosis of teratozoospermia that forces unnecessary ICSI treatment in couples treatable by IVF [29].

No single biomarker is a universal indicator of male infertility and treatment outcome; however, the SPTRX3-based assay could be combined with other immunocytochemical and cytochemical tests such as the ubiquitin-based sperm quality assay [16] or a test of sperm acrosomal status based on lectin labeling [7]. SPTRX3 is a unique marker because it is a well characterized, germline-specific protein with a distinct localization pattern in spermatozoa, and there is no need to measure its relative abundance in individual cells to decide which cells are "positive" and which are "negative." Most normal spermatozoa do not contain amounts of SPTRX3 detectable by immunofluorescence. Simply counting positive and negative spermatozoa is straight-forward and, if desired, such a test gives numbers that could be used to set up clear cutoffs for normal and infertile males. However, thresholds will be different for manual, epifluorescence microscopy based assessments as opposed to automated flow cytometric measurement. Discriminant function analysis of flow cytometric data and clinical diagnosis showed that the mean % of SPTRX3-positive spermatozoa (%M3) was for 11.6% in presumed fertile men vs. 18.6% in the clinically diagnosed infertile men (**Supplemental Statistics – ANALYSIS IV in File S1**). The cutoff values of 12.5 and 15% were found to have a good balance of sensitivity and specificity in ROC analysis (**Table S1 in File S1**). A 10% cutoff value had sensitivity close to 90%, but this was at the expense of specificity. The threshold/cutoff levels for an infertile male could also differ between IVF patients (e.g. 7.5 or 10% positive) and ICSI patients (e.g.15 or 17.5%). Thus, SPTRX3-based test could be used as a decision making tool when physicians have to decide whether to use intrauterine insemination, IVF, or ICSI. For example, a treatment with intrauterine insemination could be used in cases when a male partner's SPTRX3 levels are below 10% positive spermatozoa, IVF for men with between 10–15% SPTRX3 positive spermatozoa, and ICSI for men with >15% positive spermatozoa.

Similar to flow cytometric SPTRX3 analysis, the simplified, light microscopic analysis revealed higher pregnancy rates in couples with low SPTRX3 levels (**Table S6 in File S1**). While the more sensitive flow cytometric analysis would be preferable, the simplified light microscopic test could become a valuable tool for clinical semen evaluation wherever flow cytometry is not convenient or available. This could be done either by epifluorescence microscopy (direct conjugation of a fluorescent probe to anti-SPTRX3 antibody), or by simple transmitted light microscopy using anti-SPTRX3 antibody conjugated to horse radish peroxidase and developed by applying alkaline phosphatase or DAB. To further facilitate sample staining, sperm spreads would be fixed by methanol and dried directly on the microscopy slides. Even so, development of simplified protocols for flow cytometric semen analysis is necessary. As shown in Fig. 3 H, spermatozoa can be labeled with antibodies without previous fixation, i.e. by a

Table 3. SPTRX3 levels and ART outcomes in 72 male infertility patients divided by etiology.

Aethiology	A	AT	OA	OAT	AZ*	Other**	AVG/Total
Mean %M3 SPTRX3	18.4	14.8	28.2	18.4	25.6	17.6	18.7
SE	2.6	2.5	7.2	1.6	8.4	3.9	1.2
N	14	9	4	33	3	9	72
Pregnant/total (%)	2/14 (14%)	4/9 (44%)	0/4 (0%)	12/33 (36%)	3/3 (100%)	2/9 (22%)	23/72 (32%)
ICSI-treated/total (%)	12/14 (86%)	9/9 *** (100%)	4/4 (100%)	33/33 (100%)	3/3 (100%)	9/9 (100%)	70/72 (97%)

Most frequent etiologies included asthenozoospermia (A), astheno-teratozoospermia (AT), oligo-asthenozoospermia (OA), and oligo-astheno-teratozoospermia (OAT). One patient had obstructive azoospermia and one had obstructive oligo-teratozoospermia. Other, less frequent etiologies included teratozoospermia (2 patients), obstructive (1), vasectomy (1), varicocele (1), anti-sperm antibodies (2) and asthenozoospermia with anti-sperm antibodies (1). One couple reported failed IVF before being treated by ICSI. Couples diagnosed with combined male & female, female-only or idiopathic infertility excluded from this analysis/table.

A = asthenozoospermia.

AT = astheno-teratozoospermia.

OA = oligo-asthenozoospermia.

OAT = oligo-astheno-teratozoospermia.

*Obstructive.

**Other = teratozoospermia (2 patients), oligo-teratozoospermia, obstructive (1), vasectomy (1), varicocele (1), anti-sperm antibodies (2), asthenozoospermia with anti-sperm antibodies (1).

***One couple reported failed IVF before being treated by ICSI.

doi:10.1371/journal.pone.0061000.t003

mild permebilization and immunolabeling. Permebilization kills spermatozoa but in this case, it cannot be omitted because the SPTRX3 antigen is concealed under the plasma membrane of the membrane-intact spermatozoa. This protocol will address the major disadvantage of SPTRX3 test compared to other flow cytometry based sperm test such as SCSi or TUNEL, i.e. the lengthy, multi-step processing. This approach would benefit the new generation of dedicated sperm analysis flow cytometers such as Easy Cyte Plus, a capillary flow-based device with pre-set sperm tests, used to analyze small volumes of sperm suspensions [30]. The SPTRX3 based test may be a valuable addition to the aforementioned flow cytometric tests. Out of five male infertility patients tested by SCSi in the present cohort, none had the DNA fragmentation index (DFI) above the threshold level of 20% (Mean DFI = $7.8 \pm 2.2\%$; range 2–14%). However, the average %M3 SPTRX3 for these five patients was $25.1 \pm 7.0\%$ (range 7.8–50.0%), compared to $18.7 \pm 1.2\%$ %M3 of the entire cohort of male infertility patients. Future trials will be designed to examine the relationship between SPTRX3 retention and aberrant sperm chromatin structure.

The SPTRX3-positive spermatozoa most likely correspond to spermatozoa commonly referred to as “immature sperm” [31]. Superfluous cytoplasm can be very conspicuous in some of these spermatozoa, but difficult to detect by conventional light microscopy in others, even with high magnification lenses and DIC contrast optics. The use of SPTRX3 as a biomarker could allow clinicians to identify defective spermatozoa during semen analysis that would be undetectable to conventional semen evaluation. The SPTRX3 based method is robust, and as demonstrated here, capable of detecting sperm defects in men from couples diagnosed with idiopathic infertility. Altogether, the present study documents the relationship between SPTRX3 levels and pregnancy rates after ART, and the effect of SPTRX3 on quality of zygotes (number of pronuclei); it also identified differences in semen content of SPTRX3 and phenotypes of its retention between male patients from couples treated by ICSI and those treated by conventional IVF. Consequently, it may be possible, and necessary to set the threshold levels for normal/elevated semen SPTRX3 content differently for these two cohorts of infertility patients. Altogether, SPTRX3 protein is a candidate biomarker of sperm dysfunction that is relatively independent of

clinical semen parameters, and relevant to decision making in ART.

Materials and Methods

Semen Samples and Study Design

Semen samples were donated by men from 239 consenting couples, free of HIV and any other detectable contagious diseases, presenting for infertility treatment at the Assisted Fertilization Medical Center, Clinique Monplaisir, Lyon, France. Semen was collected on the day of IVF/ICSI and the leftover was sample cryopreserved within two after collection hours. Identities of donors were not disclosed to researchers involved in this study. All couples also consented to sharing of diagnostic data and treatment outcome-data. Couples were classified and assigned as follows: Female infertility included hydrosalpinx, endometriosis and polycystic ovary syndrome (PCOS); these couples were assigned to IVF since their sperm parameters were within acceptable limits by WHO criteria. This group also included ovarian insufficiency revealed by ultrasonographic baseline antral follicle count, associated with other pathologies; such cases were treated by ICSI. Male and combined male and female infertility was diagnosed based on semen analysis, as described below. Clinical indications of male infertility, as defined by WHO, included asthenozoospermia (A), astheno-teratozoospermia (AT), oligo-asthenozoospermia (OA) and oligo-astheno-teratozoospermia (OAT). Cases of obstructive azoospermia (AZ), obstructive OAT, teratozoospermia, obstructive OT, azoospermia due to vasectomy, varicocele, and anti-sperm antibodies were present. In vasectomy cases and cases of obstructive OAT due to inflammation, spermatozoa for ICSI were collected from testis. Five male infertility patients were tested for chromatin structure/DNA fragmentation by SCSi at a commercial laboratory, but all five had acceptable DNA-fragmentation index ($<20\%$ DFI). Generally, IVF was used in cases with acceptable progressive motility, while cases of OAT were treated by ICSI. Idiopathic infertility (no clinical symptoms or pathologies, and no previous history of andrological problems in male partners) were treated by ICSI if they reported previous failures with intrauterine insemination (IUI). If there was no history of IUI, couples were assigned to IVF

treatment. In several cases, couples were assigned to ICSI treatment because of reported IVF failure.

Male infertility was diagnosed by applying conventional WHO cutoff values valid at the time of sample collection (2002–2003) for sperm count (C), semen volume (V), total motility (M), progressive motility (PR). Percentage of spermatozoa with normal morphology (NX; % normal spermatozoa) was established by using David's classification [32,33], which was the most common method for sperm morphology assessment at the time of treatment in France, where all samples and clinical parameters for this study were collected. Volume was measured with a calibrated 15 ml Falcon tube. Spermatozoa were counted using a Thoma Chamber at a lens magnification of 10 or 20 \times ; spermatozoa were immobilized using 36% formaldehyde and stained with methylene blue. Sperm morphology was assessed by Harris and Shorr staining. Percent of necrotic spermatozoa (NEC) was assessed by Williams test (eosin staining). Clinical data were provided to researcher after the completion of flow cytometric data collection. Couples that had ICSI following a failed IVF treatment are included in the ICSI-group for the purpose of analysis. Conventional semen evaluations and cryopreservation were performed at Clinique Monplaisir, Lyon, France. Analyzed samples were cryopreserved in sperm freezing medium (Medicult Origio), in which they were diluted progressively to 1:1 v/v ratio during a ten-minute incubation at 20°C. Slow cooling from 20°C to -40°C at 2°C/minute was followed by plunging in liquid nitrogen. Cryopreserved sperm samples were processed and analyzed by flow cytometry and epifluorescence microscopy at the University of Missouri, under an approved Internal Review Board (IRB) protocol.

All 239 samples were analyzed by flow cytometry. A randomly chosen subset of 150 samples was examined by epifluorescence microscopy to assess the percentage of SPTRX-3 positive cells (100 spermatozoa examined randomly per slide), and the data were correlated with the flow cytometric data. Both SPTRX3 assays were done on semen samples left over from ART treatment. Western blotting trials (**Figure S1 in File S1**) were conducted on three samples from the patients diagnosed with extreme male infertility (dysplasia of the fibrous sheath) and on three samples from presumed fertile donors, purchased from the Fairfax Cryobank, Fairfax, VA. These trials were designed to confirm the specificity of the SPTRX3 antibody used for flow cytometry, and to explore a possibility of SPTRX3 quantification based on densitometry technique.

ART Treatment, and Evaluation of Embryos and Pregnancy Rates

Spermatozoa for both IVF and ICSI were purified on a 90%/70% PureSperm density gradient by centrifugation at 250 \times g, diluted and washed at 1,350 \times g with IVF medium (Medicult, Origio France, Limonest, FR). Sperm pellets were resuspended in 300 μ l of IVF medium for IVF or in 100 μ l for ICSI. Spermatozoa were incubated for 1 hour at 37°C and 5.5% CO₂ before ART treatment. Fertilization was performed with 100,000 spermatozoa (125,000/ml) and a maximum of 4 oocytes. *In vitro* fertilization was performed in IVF Medium (MediCult, Origio France) supplemented with sodium pyruvate and synthetic medium replacement (SSR; Origio France). A female patient was considered pregnant if her hCG was above 1000 UI and a gestational sac was detected by ultrasonography. Spermatozoa for ICSI were immobilized in clinical grade PVP medium with HEPES, sodium pyruvate and SSR. Individual spermatozoa for ICSI were selected at a 1,000 \times magnification based on morphology (David's classification; [32,33]). In several teratospermic patients (severe oligo-asthenoteratozoospermia), it was impossible to find morphologically

normal spermatozoa. The embryos were cultured in Global medium (LifeGlobal; lifeglobal.com). Embryos were evaluated on day 2, 48 hrs post oocyte pick-up, applying the following criteria of normal morphology: Minimum of 4 cells and maximum of 6 on day 2, with regular blastomere size and homogeneous cytoplasm, with <10 % of exudate (cytoplasmic fragments). Only embryos that met the above criteria were used for cryopreservation. Embryos were cultured *in vitro* for up to 6 days (blastocyst stage). The embryos which were not transferred or cryo-preserved on day 2 were re-evaluated on day 6, but the results of the second cryopreservation were not included in this study.

Sperm Processing for Flow Cytometry

The sperm samples were stored and shipped in individual straws in liquid nitrogen, and processed by a method modified from sperm ubiquitin assays described previously [34]. Five microliters of Tyrode-Lactate-HEPES medium (TLH) were added per tube to 15 ml Falcon polypropylene centrifuge tubes (Becton Dickinson, Franklin Lakes, NJ), and the thawed contents of each straw were added to the correctly labeled tubes. The use of similar size polystyrene tubes was avoided deliberately as we found previously that many spermatozoa adhere to their walls and are lost during centrifugation. The mixture was spun for 5 minutes at 350 \times g in a bench-top, fixed angle rotor centrifuge (Centrif; Fischer Scientific) and the supernatant was removed by a Pasteur pipette attached via flexible tube to an air pump, making sure to not disturb the sperm pellet at the bottom of the tube. Next, 5 ml of 2% formaldehyde (EM grade; Polyscience, Warrington, PA) in phosphate buffered saline (PBS) were added to each tube and vortexed. The samples were fixed for 40 min at room temperature (RT) and washed by centrifugation in 8 ml of PBS. After complete removal of the washing buffer, 80 μ l of PBS were added per tube. To permeabilize the cells and block potential non-specific antibody binding, 10 μ l of 20 % normal goat serum (NGS; Sigma) in PBS with 1 % Triton-100 (Sigma) were added to each tube. After one hour of incubation at room temperature, 10 μ l of affinity purified, peptide-specific anti-SPTRX3 antibody [14], diluted 1:30 in PBS with 1% NGS and 0.1% TX-100, were added to each tube. The specificity and quantitative nature of this antibody is demonstrated by Western blotting of semen samples from three presumed fertile donors and three patients diagnosed with heritable male infertility (**Figure S1 in File S1; Table S10 in File S1**). The samples were incubated overnight at 4°C. The next day, 10 μ l of goat-anti rabbit IgG conjugated to a red fluorescent dye TRITC (GAR-TRITC; Invitrogen-Zymed; Carlsbad, CA), diluted 1:9 in PBS with 1% NGS and 0.1% TX-100, were added to each tube. Samples were incubated for 40 min at RT, and washed with 5 ml of PBS-BSA. The washed sperm pellets were resuspended in 500 μ l of pure PBS and transferred into 5 ml Falcon flow cytometry tubes (Becton Dickinson, Franklin Lakes, NJ) with cell strainer caps, to remove large debris and agglutinated cells. A shortened version of this protocol was tested on several samples in which fixation and blocking were omitted and the frozen-thawed samples were incubated for 20 min with anti-SPTRX3 antibody diluted in PBS with 1%NGS and 0.1% TX-100. After 20 min, the concentrated GAR-TRITC was added and the samples were viewed under epifluorescence microscope after additional 20 min. of incubation (representative results shown in **Figure 3H**). None of these samples were included in the flow cytometric analysis.

Flow Cytometric Analysis

Flow cytometry was performed using FacsScan flow cytometer (Becton Dickinson Corp.), measuring 10,000 cells per sample at

568 nm light wavelength. Acquired relative intensities of TRITC labeling were plotted as histograms and divided into three areas of low (marker area M1), medium (marker area M2) and high relative intensity (marker area M3; see **Figure 1A, 1B**), essentially as described for ubiquitin, PAFR and 15-LOX proteins in animal spermatozoa [35,36]. The marker area M1 contains the low-fluorescent sperm fragments and debris. Marker area M2 delimits background fluorescence of intact spermatozoa not carrying SPTRX3, with some content of larger debris particles. Marker area M3 contains the spermatozoa, large sperm-derived debris and immature sperm forms with accumulated, fluorescently labeled SPTRX3 protein (SPTRX3-positive spermatozoa). Blank negative control samples generated by the replacement of anti-SPTRX3 antibody with a non-immune rabbit serum were evaluated in the same trial under identical conditions. For each sample, the following flow cytometric parameters were recorded and entered in MS-Excel tables: Percentage of total cell numbers within marker areas M1-M3 (%M1, %M2, %M3), median fluorescence of all cells in a sample and of the cell subpopulations within marker areas M1-M3 (SPTRX3 Median All, M1, M2, M3), geometric mean of relative fluorescence of all cells in sample (GeoMean), mean relative fluorescence of all cells (Mean All, Mean M1-M3) and cells in M1-M3, coefficient of variation (CV; normalized standard deviation $CV = SD/Mean$), and Peak Channel. Additionally, the % of flow cytometric events registered in visible light scatter as cells of prevailing size out of all events within the whole measured sample were recorded as the % Total values, reflective of relative ratio of combined high and low fluorescence spermatozoa to low-fluorescent small debris in a sperm sample (see **Figure 1A', 1B'**).

Statistical Analysis

Regression analyses were conducted in SAS using *proc glm* procedures to investigate the relationship between the SPTRX3 levels and the clinical indication and treatment variables. Logistics regression analysis was conducted using *proc logit* to investigate the relationship between the pregnancy rate and the SPTRX3 levels, female age variables and treatment assignment. SAS *proc corr* procedure was used to perform a Spearman rank correlation study of relationship between conventional and flow cytometric semen parameters. Discriminant analysis was performed using SAS *proc discrim* and *proc stepdisc* procedures. Cutoff values for diagnosis of male infertility based on %M3 value were established by Receiver Operator Characteristic (ROC) curve analysis. Descriptive statistics and Pearson's correlation coefficients were generated by using statistical tools package in MS-Excel. Values of %M3 and GeoMean were found to be most informative and are listed in the Tables. The value of % TOTAL also showed a strong correlation with some of the clinical semen parameters.

Analysis by Epifluorescence Microscopy

A randomly chosen subset of 150 samples were examined under a Nikon Eclipse 800 epifluorescence-equipped light microscope to determine the percentage of SPTRX3-positive cells, by using the processed, but unexposed sample remnants left over from flow cytometric measurements. Following the flow cytometric analysis, each leftover sample was transferred from a 5 ml flow cytometry tube to a 1.5 ml Eppendorf tube, sealed and stored at 4°C until mounting and analysis. Filtered PBS was added up to approximately the 0.5 ml mark and 2.5 µl of DNA dye DAPI (200 µg/ml stock) were added to each tube. The samples were spun for 1 minute at 500×g in Sorvall Biofuge Fresco centrifuge to concentrate the sperm in a pellet, of which 7.5 µl were mounted on a clean slide. Slides were covered by coverslips, sealed with

clear nail polish and stored at 4°C until evaluation. At least 100 spermatozoa were counted per slide and were categorized into two different groups, SPTRX3-positive cells and SPTRX3-non positive cells. Positive cells were further divided by the association of SPTRX3 labeling with the sperm head or sperm tail. The sperm head category had SPTRX3 in the nuclear vacuoles while the sperm tail category included labeling in the redundant cytoplasm around the proximal midpiece as well as the association of SPTRX3 extending from the sperm tail connecting piece toward the post-acrosomal sheath of the sperm head. The percentages of all SPTRX3-positive spermatozoa and the percentages of head/tail-positive spermatozoa were entered in MS-Excel tables and correlated with flow cytometric data. Representative images were acquired by a CoolSnap HQ CCD camera operated by MetaMorph software, using appropriate epifluorescence filters on a Nikon Eclipse E800 microscope. Images were edited using Adobe® Photoshop CS5 Extended version (Adobe Systems, Inc., San Jose, CA, USA).

Supporting Information

File S1 Supplemental figures and tables. Figure S1. Western blotting of SPTRX3 in semen of three ART patients and three presumed fertile donors (semen parameters are shown in Table S10). Relative levels of SPTRX3 (top panel) and beta-tubulin (loading control; middle panel) are shown for three presumably fertile sperm bank donors with acceptable clinical semen parameters (lanes 1-3) and three teratozoospermic infertile men (lanes 4-6) suffering from dysplasia of the fibrous sheath. Diagram of SPTRX3/tubulin band density ratios is shown on the bottom. Note the high density of SPTRX3 band in donor #1, who was presumed fertile. Figure S2. Smoking has a modest effect on sperm SPTRX3 levels. Heavy smokers consuming 15-30 cigarettes per day had higher average levels of sperm SPTRX3 than other groups shown. Of note, two thirds (10/15) of these heavy smokers had indication/clinical diagnosis of male infertility. The numeric difference between smokers consuming 2-5 cigarettes per day and smokers consuming 15-30 cigarettes per day, was not statistically significant ($p>0.1$). Figure S3. Scatter diagram illustrating the relationship between subjective, light microscopic assessment of sperm SPTRX3 content (% spermatozoa with SPTRX3-positive heads; x-axis) and flow cytometry (%M3 SPTRX-value; y-axis). This simple light microscopic analysis was conducted as a potential precursor of a test suitable for clinical andrology laboratories. Samples from 150 randomly chosen donors, processed for flow cytometry, were re-evaluated by epifluorescence microscopy for the percentage of SPTRX3 positive sperm heads, sperm tails, and total % of SPTRX3 positive spermatozoa. Correlations were found between all three categories of light microscopic evaluation and % of SPTRX3-positive spermatozoa as measured by flow cytometry (%M3). The highest correlation coefficient ($r=0.46$) was between % SPTRX3-positive sperm heads by light microscopy and %M3 SPTRX3 by flow cytometry (see Table S4B). Table S1. Receiver Operator Characteristic (ROC) analysis. As anticipated, Specificity increases at the expense of Sensitivity as the cutoff values increase. The area under the ROC curve is 0.74, which shows that the %M3 performs well for predicting the male infertility. Table S2. Semen SPTRX3 levels and live births. Pregnancy outcomes were available for 57/60 pregnant couples. One of those 57 pregnancies was an ectopic pregnancy in a case of female-only infertility; it is not included in the above table. Live birth was achieved in 81% (46/57) of those analyzed pregnant couples. One of those three male factor patients had a vasectomy. Table S3. Parameters of zygotic development in 239 couples

divided into subgroups based on percentages of SPTRX3-positive spermatozoa (A) or clinical indication (B). SPTRX3 values, but not the clinical indication, were predictive of good zygotic development after IVF or ICSI. Couples with lowest SPTRX3 levels (A, top row, <5% M3) produced the highest percentage of normal, two-pronuclear (2 PN) zygotes out of all fertilized oocytes (A, column 8), and also when calculated based on all oocytes harvested (A, column 9). These couples also produced the most embryos suitable for transfer or cryopreservation (column 13). Note that couples with low or medium levels of SPTRX3 produced more 2PN zygotes per couple on average than couples with >15% SPTRX3 (A, column 10). Idiopathic couples in which men recorded more than 15% SPTRX3-positive spermatozoa had the lowest yields of two-pronuclear zygotes. Numbers shown in red are highest & lowest values for each column. No significant correlations were found between parameters of early embryo development and flow cytometric SPTRX3 levels. Table S4. Relationship between the clinical treatment assignment and various sperm quality parameters. Table S5. A: Pregnancy rates in 150 infertile couples, divided by percentages of SPTRX3-positive spermatozoa. In accordance with flow cytometric SPTRX3-data, couples with lowest levels of SPTRX3 had highest pregnancy rate (column 2). Also similar to flow cytometric results, the percentage of couples treated by ICSI increased progressively with sperm SPTRX3 content (column 6). Spermatozoa were evaluated for the presence of SPTRX3 in the sperm head (B) or tail (C; combined head and tail labeling has not been observed), adding up to third category of total SPTRX3-positive spermatozoa (A). Numbers shown in red are highest & lowest values for each column. With the exception of one SPTRX3 parameter (A-% of all positive spermatozoa), pregnancy rates (column #2) in light microscopic analysis were dose-dependent on SPTRX3 values. B: Correlations between light microscopic SPTRX3-evaluation (STIX assay) and % of SPTRX3-positive spermatozoa as measured by flow cytometry. Bold font indicates highest correlation coefficients for flow cytometric and light microscopic parameters. Table S6. Sperm SPTRX3 levels and oocyte quality parameters in 238 couples divided by female partners' age, with the threshold of 35 years of age. Female age subgroups (in rows) were further divided based on male partners' semen content of SPTRX3-positive spermatozoa (Column 4), and based on the treatment (IVF or ICSI, columns 6 & 7). Regardless of female partner's age, the combined IVF & ICSI pregnancy rates (column 9) as well as the ICSI pregnancy rates (column 10) were numerically higher when the male partner had <10% SPTRX3-positive spermatozoa. Table S7. Analysis of subgroups divided by indication (male or female infertility) and female age.

References

1. Evenson DP, Larson KL, Jost LK (2002) Sperm chromatin structure assay: its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques. *J Androl* 23: 25–43.
2. Hughes CM, Lewis SE, McKelvey-Martin VJ, Thompson W (1996) A comparison of baseline and induced DNA damage in human spermatozoa from fertile and infertile men, using a modified comet assay. *Mol Hum Reprod* 2: 613–619.
3. Baccetti B, Collodel G, Piomboni P (1996) Apoptosis in human ejaculated sperm cells (notulae seminologicae 9). *J Submicrosc Cytol Pathol* 28: 587–596.
4. Aitken RJ, De Iulius GN (2007) Origins and consequences of DNA damage in male germ cells. *Reprod Biomed Online* 14: 727–733.
5. Lewis SE (2007) Is sperm evaluation useful in predicting human fertility? *Reproduction* 134: 31–40.
6. Garner DL, Thomas CA, Joerg HW, DeJarnette JM, Marshall CE (1997) Fluorometric assessments of mitochondrial function and viability in cryopreserved bovine spermatozoa. *Biol Reprod* 57: 1401–1406.
7. Cross NL, Morales P, Overstreet JW, Hanson FW (1986) Two simple techniques for detecting acrosome-reacted human sperm. *Gamete Research* 15: 213–226.
8. Graham JK, Kunze E, Hammerstedt RH (1990) Analysis of sperm cell viability, acrosomal integrity, and mitochondrial function using flow cytometry. *Biol Reprod* 43: 55–64.
9. Barroso G, Morshedi M, Oehninger S (2000) Analysis of DNA fragmentation, plasma membrane translocation of phosphatidylserine and oxidative stress in human spermatozoa. *Hum Reprod* 15: 1338–1344.
10. Sutovsky P, Lovercamp K (2010) Molecular markers of sperm quality. *Soc Reprod Fertil Suppl* 67: 247–256.
11. Lillig CH, Holmgren A (2007) Thioredoxin and related molecules – from biology to health and disease. *Antioxid Redox Signal* 9: 25–47.
12. Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, et al. (2008) TRPC channel activation by extracellular thioredoxin. *Nature* 451: 69–72.
13. Miranda-Vizuet A, Sadek CM, Jimenez A, Krause WJ, Sutovsky P, et al. (2004) The mammalian testis-specific thioredoxin system. *Antioxid Redox Signal* 6: 25–40.

Combined and idiopathic cases were not included in analysis. Table S8. Correlations between flow cytometric SPTRX3 values and clinical semen parameters. R-values by Person's correlation analysis are shown. Most significant values are printed bold. In general, SPTRX3 values correlate negatively with sperm count, motility, and percentage of morphologically normal spermatozoa in samples, assessed by conventional light microscopic semen evaluation. Ratio of spermatozoa to debris (%TOTAL) correlates positively with sperm count, motility and normal morphology. Bold font indicates highest correlation coefficients. Table S9. Spearman correlations between the most informative flow cytometric SPTRX3 parameters and the conventional semen parameters (the second numbers in the cells are the p-values). Table S10. Conventional semen parameters for semen samples used for Western blotting. Table S11. Discriminant analysis using SAS PROC discrim and stepdisc procedures applied to study the relationship of pregnancy rate with the sperm quality parameters and SPTRX3 levels, with consideration of treatment assignments. Table S12. Structure matrix of the discriminant analysis conducted to study the relationship of the treatment assignment, SPTRX3 and the sperm quality parameters. Table S13. Variables and treatment groups in the discriminant analysis conducted to study the relationship of the treatment assignment, SPTRX3 and the sperm quality parameters. Table S14. Canonical structure matrix of the discriminant analysis using SAS proc discrim procedure, conducted to explore the relationships between the clinically diagnosed male infertility and sperm quality parameters. Table S15. Means of the nine variables shown separately for infertile and fertile male in the discriminant analysis (SAS proc discrim) conducted to explore the relationships between the clinically diagnosed male infertility and sperm quality parameters. (PDF)

Acknowledgments

We thank anonymous consenting patients for donating samples for this research. Clerical and editorial support by Ms. Kathy Craighead is gratefully acknowledged. We are very indebted to Dr. Hector Chemes for his comments on the manuscript and for providing samples from DFS-patients.

Author Contributions

Conceived and designed the experiments: PS CO AMV. Performed the experiments: CB MS JC CO VYR GM. Analyzed the data: JQ PS. Contributed reagents/materials/analysis tools: AMV CO VYR PS. Wrote the paper: CB PS CO AMV JQ.

14. Jimenez A, Zu W, Rawe VY, Pelto-Huikko M, Flickinger CJ, et al. (2004) Spermatoocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis. *J Biol Chem* 279: 34971–34982.
15. Buckman C, George TC, Friend S, Sutovsky M, Miranda-Vizuete A, et al. (2009) High throughput, parallel imaging and biomarker quantification of human spermatozoa by ImageStream flow cytometry. *Syst Biol Reprod Med* 55: 244–251.
16. Ozanon C, Chouteau J, Sutovsky P (2005) Clinical adaptation of the sperm ubiquitin tag immunoassay (SUTI): relationship of sperm ubiquitylation with sperm quality in gradient-purified semen samples from 93 men from a general infertility clinic population. *Hum Reprod* 20: 2271–2278.
17. Jimenez A, Johansson C, Ljung J, Sagemark J, Berndt KD, et al. (2002) Human spermatid-specific thioredoxin-1 (Sptrx-1) is a two-domain protein with oxidizing activity. *FEBS Lett* 530: 79–84.
18. Miranda-Vizuete A, Ljung J, Damdimopoulos AE, Gustafsson JA, Oko R, et al. (2001) Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. *J Biol Chem* 276: 31567–31574.
19. Sadek CM, Jimenez A, Damdimopoulos AE, Kieselbach T, Nord M, et al. (2003) Characterization of human thioredoxin-like 2. A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme. *J Biol Chem* 278: 13133–13142.
20. Gomez E, Buckingham DW, Brindle J, Lanzafame F, Irvine DS, et al. (1996) Development of an image analysis system to monitor the retention of residual cytoplasm by human spermatozoa: correlation with biochemical markers of the cytoplasmic space, oxidative stress, and sperm function. *J Androl* 17: 276–287.
21. Aitken RJ, Buckingham DW, Carreras A, Irvine DS (1996) Superoxide dismutase in human sperm suspensions: relationship with cellular composition, oxidative stress, and sperm function. *Free Radic Biol Med* 21: 495–504.
22. Casano R, Orlando C, Serio M, Forti G (1991) LDH and LDH-X activity in sperm from normospermic and oligozoospermic men. *Int J Androl* 14: 257–263.
23. Huszar G, Vigue L, Corrales M (1988) Sperm creatine phosphokinase activity as a measure of sperm quality in normospermic, variablespermic, and oligospermic men. *Biol Reprod* 38: 1061–1066.
24. Keating J, Grundy CE, Fivey PS, Elliott M, Robinson J (1997) Investigation of the association between the presence of cytoplasmic residues on the human sperm midpiece and defective sperm function. *J Reprod Fert* 110: 71–77.
25. Zini A, Defreitas G, Freeman M, Hechter S, Jarvi K (2000) Varicocele is associated with abnormal retention of cytoplasmic droplets by human spermatozoa. *Fertil Steril* 74: 461–464.
26. Cooper TG (2005) Cytoplasmic droplets: the good, the bad or just confusing? *Hum Reprod* 20: 9–11.
27. Aitken RJ, Wingate JK, De Iuliis GN, Koppers AJ, McLaughlin EA (2006) Cis-unsaturated fatty acids stimulate reactive oxygen species generation and lipid peroxidation in human spermatozoa. *J Clin Endocrinol Metab* 91: 4154–4163.
28. Aitken RJ, Sawyer D (2003) The human spermatozoon – not waving but drowning. *Adv Exp Med Biol* 518: 85–98.
29. Keegan BR, Barton S, Sanchez X, Berkeley AS, Krey LC, et al. (2007) Isolated teratozoospermia does not affect in vitro fertilization outcome and is not an indication for intracytoplasmic sperm injection. *Fertil Steril* 88: 1583–1588.
30. Odhiambo JF, Sutovsky M, DeJarnette JM, Marshall C, Sutovsky P (2011) Adaptation of ubiquitin-PNA based sperm quality assay for semen evaluation by a conventional flow cytometer and a dedicated platform for flow cytometric semen analysis. *Theriogenology* 76: 1168–1176.
31. Huszar G, Ozkavukcu S, Jakab A, Celik-Ozenci C, Sati GL, et al. (2006) Hyaluronic acid binding ability of human sperm reflects cellular maturity and fertilizing potential: selection of sperm for intracytoplasmic sperm injection. *Curr Opin Obstet Gynecol* 18: 260–267.
32. Auger J, Eustache F (2000) Standardisation de la classification morphologique des spermatozoïdes humains selon la méthode de David modifiée. *Andrologie* 10: 358–372.
33. David G., Bisson JP, Czyglik F, Jouannet P, Gernigon C (1975) Anomalies morphologiques du spermatozoïde humain. 1) Propositions pour un système de classification. *J Gynecol Obstet Biol Reprod Suppl.* 1: 17–36.
34. Sutovsky P, Terada Y, Schatten G (2001) Ubiquitin-based sperm assay for the diagnosis of male factor infertility. *Hum Reprod* 16: 250–258.
35. Sutovsky P, Plummer W, Baska K, Peterman K, Diehl JR, et al. (2007) Relative levels of semen platelet activating factor-receptor (PAFr) and ubiquitin in yearling bulls with high content of semen white blood cells: implications for breeding soundness evaluation. *J Androl* 28: 92–108.
36. Lovercamp KW, Safranski TJ, Fischer KA, Manandhar G, Sutovsky M, et al. (2007) Arachidonate 15-lipoxygenase and ubiquitin as fertility markers in boars. *Theriogenology* 67: 704–718.

FILE S1 - SUPPLEMENTAL INFORMATION




Figure S1: Western blotting of SPTRX3 in semen of three ART patients and three presumed fertile donors (semen parameters are shown in **Table S10**). Relative levels of SPTRX3 (top panel) and beta-tubulin (loading control; middle panel) are shown for three presumably fertile sperm bank donors with acceptable clinical semen parameters (lanes 1-3) and three teratozoospermic infertile men (lanes 4-6) suffering from dysplasia of the fibrous sheath. Diagram of SPTRX3/tubulin band density ratios is shown on the bottom. Note the high density of SPTRX3 band in donor #1, who was presumed fertile.




Figure S2: Smoking has a modest effect on sperm SPTRX3 levels. Heavy smokers consuming 15-30 cigarettes per day had higher average levels of sperm SPTRX3 than other groups shown. Of note, two thirds (10/15) of these heavy smokers had indication/clinical diagnosis of male infertility. The numeric difference between smokers consuming 2-5 cigarettes per day and smokers consuming 15-30 cigarettes per day, was not statistically significant ($p>0.1$).





Figure S3: Scatter diagram illustrating the relationship between subjective, light microscopic assessment of sperm SPTRX3 content (% spermatozoa with SPTRX3-positive heads; x-axis) and flow cytometry (%M3 SPTRX-value; y-axis). This simple light microscopic analysis was conducted as a potential precursor of a test suitable for clinical andrology laboratories. Samples from 150 randomly chosen donors, processed for flow cytometry, were re-evaluated by epifluorescence microscopy for the percentage of SPTRX3 positive sperm heads, sperm tails, and total % of SPTRX3 positive spermatozoa. Correlations were found between all three categories of light microscopic evaluation and % of SPTRX3-positive spermatozoa as measured by flow cytometry (%M3). The highest correlation coefficient ($r=0.46$) was between % SPTRX3-positive sperm heads by light microscopy and %M3 SPTRX3 by flow cytometry (see Supplemental Table 4 B).

Materials & Methods for Western Blotting and Computerized Densitometry

Western blotting was performed to validate the SPTRX3 antibody and to explore the relationship between the total amount of SPTRX3 in spermatozoa of men with good and poor clinical semen parameters. As described previously [36], semen samples were washed, extracted in 50 mM Tris HCl, 500 mM NaCl, 0.5% Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and a 1:1,000 dilution of protease inhibitor cocktail (chymostatin, leupeptin, antipain, and pepstatin A; Sigma, St. Louis, MO, USA), and boiled for 3 min and loading on a 4-15% gradient tris-glycine gel (Bio-Rad Laboratories, Hercules, CA, USA). Protein load per lane was 30 µg. Five microliters of ProSieve® Color Protein Markers (Cambrex, East Rutherford, NJ, USA) diluted in 5 µl of loading buffer were used as the molecular mass marker. Electrophoresis was performed for one hour using the Fischer Bioscience vertical electrophoresis system. After electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore Corp., Bedford, MA, USA) using a wet transfer system (Owl Scientific, Inc., Woburn, MA, USA). The membrane was washed in 0.25% Tris Base Saline (TBS)-Tween 20, five times for 4 min on a platform rocker (Barnstead International, Dubuque, IA, USA). The membrane was then incubated for one hour in 0.25% TBS-Tween 20 and 10% non-fat dried milk for blocking of non-specific antibody binding, washed and incubated overnight with anti-SPTRX3 antibody diluted 1:2,000. On the second day, the membrane was washed and incubated for 1 hr with GAR-IgG HRP (Invitrogen-Zymed) in 0.25% TBS-Tween 20 and 5% non-fat dried milk. The membrane was washed, incubated for 5 min in SuperSignal® West Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA), and developed on Kodak BioMax Light Film (Kodak, New Haven, CT, USA) for 30 sec using a Hope Micro-Max table-top film processor (Hope, Warminster, PA, USA). The membrane was then stripped and re-probed overnight with mouse monoclonal antibody E7, recognizing beta tubulin (TUBB) (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), diluted 1:2,000, followed by washing and incubation with goat anti-mouse IgG-HRP, serving as a loading control and densitometric standard. Densitometry was performed by the Kodak Electrophoresis Documentation and Analysis System 290 (EDAS 290) with image capture by the Kodak DC 290 camera. Image analysis was performed by Kodak 1D Image Analysis software (Kodak Scientific Imaging Systems, New Haven, CT, USA) and the relative densities were entered in MS-Excel to calculate the SPTRX3-TUBB ratio for each sample.

TABLE S1: Receiver Operator Characteristic (ROC) analysis. As anticipated, Specificity increases at the expense of Sensitivity as the cutoff values increase. The area under the ROC curve is 0.74, which shows that the %M3 performs well for predicting the male infertility.

Cutoff for %M3	Number of men with %M3 above cutoff	TRUE Positive (TP)	TRUE negative (TN)	False negative (FN)	False Positive (FP)	Sensitivity TP/(TP+FN)	Specificity TN/(TN+FP)
50.0%	0	0	146	93	0	0.0%	100.0%
35.0%	7	6	145	87	1	6.5%	99.3%
32.5%	10	9	145	84	1	9.7%	99.3%
30.0%	16	13	143	80	3	14.0%	98.0%
27.5%	21	17	142	76	4	18.3%	97.3%
25.0%	30	23	139	70	7	24.7%	95.2%
22.5%	38	30	138	63	8	32.3%	94.5%
20.0%	46	34	134	59	12	36.6%	91.8%
17.5%	56	39	129	54	17	41.9%	88.4%
15.0%	79	49	116	44	30	52.7%	79.5%
12.5%	110	63	99	30	47	67.7%	67.8%
10.0%	166	80	60	13	86	86.0%	41.1%
7.5%	197	88	37	5	109	94.6%	25.3%
5.0%	223	90	13	3	133	96.8%	8.9%
2.5%	239	93	0	0	146	100.0%	0.0%



True positive (TP) = number of couples ABOVE cutoff value who were diagnosed with male infertility (**MIF**), including couples with combined male & female infertility

True negative (TN) = number of couples BELOW cutoff who did NOT have MIF diagnosis

False negative (FN) = number of couples BELOW cutoff who were diagnosed with MIF

False positive (FP) = number of couples ABOVE cutoff who were NOT diagnosed with MIF

Sensitivity = $TP/(TP+FN)$ = percentage of men who were diagnosed with MIF that test positive for the SPTRX3.

Specificity = $TN/(TN+FP)$ = percentage of men who don't have MIF diagnosis that test negative for the SPTRX3

TABLE S2: Semen SPTRX3 levels and live births.**TABLE S2A:**

<i>Pregnancy outcome</i>	n	%M3 SPTRX3	Number treated by ICSI (%)
Miscarriage – all couples	10	14.8 +/- 2.2	6 (60%)
Singleton – all couples	34	15.3+/-1.6	19 (56%)
Twins - all couples	12	10.5 +/- 1.4	7 (58%)
Miscarriage - male inf. couples	3	19.8+/-4.0	3 (100%)
Singleton - male inf. couples	16	18.2+/-2.7	15 (94%)
Twins - male inf. couples	3*	14.5+/-2.5	3 (100%)

Pregnancy outcomes were available for 57/60 pregnant couples. One of those 57 pregnancies was an ectopic pregnancy in a case of female-only infertility; it is not included in the above table. Live birth was achieved in 81% (46/57) of those analyzed pregnant couples.

*One of those three male factor patients had a vasectomy

TABLE S2 B:

Outcome/% M3 SPTRX3	<5%	5-9.99%	10-14.99%	>15%	TOTAL
Miscarriage – all couples	0 (0%)	2 (20%)	3 (30%)	5 (50%)	10
Singleton – all couples	3 (9%)	7 (21%)	10 (29%)	14 (41%)	34
Twins - all couples	2 (17%)	3 (25%)	5 (41%)	2 (17%)	12
All live birth couples	5 (9%)	10 (18%)	15 (26%)	16 (27%)	56
All pregnant couples	5 (8%)	13 (22%)	21 (35%)	21 (35%)	60
All non-pregnant couples	12 (7%)	44 (25%)	66 (35%)	57 (32%)	179
ALL couples	17 (7%)	57 (24%)	87 (35%)	78 (33%)	239

TABLE S3: Parameters of zygotic development in 239 couples divided into subgroups based on percentages of SPTRX3-positive spermatozoa (A) or clinical indication (B). SPTRX3 values, but not the clinical indication, were predictive of good zygotic development after IVF or ICSI. Couples with lowest SPTRX3 levels (A, top row, <5% M3) produced the highest percentage of normal, two-pronuclear (2 PN) zygotes out of all fertilized oocytes (A, column 8), and also when calculated based on all oocytes harvested (A, column 9). These couples also produced the most embryos suitable for transfer or cryopreservation (column 13). Note that couples with low or medium levels of SPTRX3 produced more 2PN zygotes per couple on average than couples with >15% SPTRX3 (A, column 10). Idiopathic couples in which men recorded more than 15% SPTRX3-positive spermatozoa had the lowest yields of two-pronuclear zygotes. Numbers shown in red are highest & lowest values for each column. No significant correlations were found between parameters of early embryo development and flow cytometric SPTRX3 levels.

TABLE S3A: Parameters of pronuclear development in couples with varied sperm SPTRX3 content												
Column 1	2	3	4	5	6	7	8	9	10	11	12	13
%M3 SPTRX3	n - couples	Total oocytes matured	Total oocytes fertilized	Total polypronuclear zygotes (%)	Total 0 PN zygotes (%)	Total 1 PN zygotes (%)	Total 2 PN zygotes produced (% of fertilized oocytes)	% 2 PN zygotes produced out of all harvested oocytes	Avg. number of 2PN zygotes produced per couple	Embryos transferred (% out of all 2 PN zygotes)	Embryos cryo-preserved (out of all 2 PN zyg)	% Embryos transferred and cryo-preserved out of all 2 PN zygotes
<5%	16	167	159	9	9	4	137 (86.2%)	82.0%	8.6	30 (21.9%)	84 (61.3%)	83.2%
5-9.99%	57	732	665	45	78	30	512 (77.0%)	69.9%	9.0	123 (24.0%)	268 (52.3%)	76.3%
10-14.99%	88	995	793	36	103	39	615 (77.6%)	61.8%	7.0	174 (28.3%)	319 (52.3%)	80.6%
>15%	78	871	679	25	65	26	563 (82.9%)	64.6%	7.2	164 (29.1%)	258 (45.8%)	74.9%
>15% idiopathic	12	148	109	6	25	2	76 (69.7%)	51.4%	6.3	25(16.9%)	38 (50.0%)	66.9%
TABLE S3B: Lack of influence of clinical indication on parameters of pronuclear development												
Male Inf.	72	818	654	25	34	23	572 (87.5%)	69.9%	7.9	162 (28.3%)	301 (52.6%)	80.9%
Female Inf.	85	963	899	59	131	51	658 (73.2%)	68.3%	7.7	168 (25.5%)	342 (52.0%)	77.5%
Combined Inf.	21	283	220	3	12	4	201 (91.4%)	71.0%	9.6	39 (19.4%)	98 (48.8%)	68.2%
Idiopathic Inf.	61	728	584	28	83	21	452 (77.4)	62.1%	7.4	127 (28.1%)	220 (48.7%)	76.8%

TABLE S4: Relationship between the clinical treatment assignment and various sperm quality parameters.

Parameter	p-value	Odds ratio*
V	0.8554	NA
PR	<0.0001	1.176
NX	<0.0001	1.067
NEC	<0.0001	0.936
M	<0.0001	1.142
C	<0.0001	1.029
Median ALL	0.0125	0.964
Median M3	<0.0001	0.978
Median M2	0.3114	NA
Median M1	0.0022	5.187
Mean all	<0.0001	0.960
Mean M3	<0.0001	0.972
Mean M2	0.3920	NA
Mean M1	0.0001	34.058
Total	<0.0001	1.088
%M3	<0.0001	0.904
%M2	<0.0001	1.141
%M1	0.4735	NA
CVALL	0.0014	0.994
CVM3	0.0357	0.99
CVM2	0.0342	0.931
CVM1	0.0006	0.837

Abbreviations:

C=sperm count

V=semen volume

M=total motility

PR=progressive motility

NX=morphology/ % normal spermatozoa

NEC=percent of necrotic spermatozoa assessed by Williams test

TABLE S5 A: Pregnancy rates in 150 infertile couples, divided by percentages of SPTRX3-positive spermatozoa. In accordance with flow cytometric SPTRX3-data, couples with lowest levels of SPTRX3 had highest pregnancy rate (column 2). Also similar to flow cytometric results, the percentage of couples treated by ICSI increased progressively with sperm SPTRX3 content (column 6). Spermatozoa were evaluated for the presence of SPTRX3 in the sperm head (**B**) or tail (**C**; combined head and tail labeling has not been observed), adding up to third category of total SPTRX3-positive spermatozoa (**A**). Numbers shown in red are highest & lowest values for each column. With the exception of one SPTRX3 parameter (A-% of all positive spermatozoa), pregnancy rates (column #2) in light microscopic analysis were dose-dependent on SPTRX3 values.

Column #	1	2	3	4	5	6
Parameter	N (couples)	% pregnant (n)	% male & combined infertility cases in this group (n)	Avg. %2 PN zygotes per couple out of all ovulated (n/total)	Avg. %2 PN zygotes per couple out of all fertilized	% treated by ICSI
A-% of all positive spermatozoa (head-positive and tail-positive, combined)						
<5%	30	37% (11)	13% (4)	59.5% (235/395)	79.1% (235/297)	267% (8/30)
5-9.99%	73	29% (23)	19% (14)	49.3% (500/1014)	74.9% (500/668)	48% (35/73)
10-14.99%	29	18% (5)	38% (11)	59.2% (252/426)	83.7% (252/301)	59% (17/29)
>15%	18	22% (4)	56% (10)	58.7% (125/213)	89.9% (125/139)	72% (13/18)
All couples	150	29% (43)	26% (39)	54.3% (1112/2048)	79.2% (1112/1405)	49% (73/150)
B-% of head only-positive spermatozoa						
<5%	103	33% (34)	19%(20)	53.6% (764/1417)	75.2% (764/1016)	44% (44/103)
5-9.99%	41	20% (8)	39% (16)	52.8% (299/566)	88.7% (299/337)	63% (26/41)
>10%	6	17% (1)	50% (3)	75.5% (49/65)	94.2% (49/52)	50 % (3/6)
C-% of tail only-positive spermatozoa						
<5%	93	33% (31)	16% (15)	51.3% (667/1301)	75.9% (667/879)	38% (35/93)
5-9.99%	46	22%(10)	39% (18)	59.7% (382/640)	84.0% (382/455)	70% (32/46)
>10%	10	20% (2)	60% (6)	58.9% (63/107)	88.7% (63/71)	60% (6/10)

TABLE S5 B: Correlations between light microscopic SPTRX3-evaluation (STIX assay) and % of SPTRX3-positive spermatozoa as measured by flow cytometry. Bold font indicates highest correlation coefficients for flow cytometric and light microscopic parameters.

	% Tail	%Head	%H&T	%M1	%M2	%M3
% Tail	1					
%Head	0.71	1				
%H&T	0.94	0.91	1			
%M1	-0.29	-0.27	-0.31	1		
%M2	-0.25	-0.41	-0.35	0.08	1	
%M3	0.33	0.46	0.42	-0.41	-0.94	1

Abbreviations:

% Tail=spermatozoa with SPTRX3 labeling in the sperm tail midpiece

%Head: spermatozoa with SPTRX3-labeling in the sperm head (mostly nuclear vacuoles)

%H&T=Combined % of spermatozoa carrying SPTRX3 in either sperm head or tail

%M1=% spermatozoa gated within marker M1 in flow cytometric histograms

%M2=% spermatozoa gated within marker M2 in flow cytometric histograms

%M3=% spermatozoa gated within marker M3 in flow cytometric histograms

Table S6: Sperm SPTRX3 levels and oocyte quality parameters in 238 couples divided by female partners' age, with the threshold of 35 years of age. Female age subgroups (in rows) were further divided based on male partners' semen content of SPTRX3-positive spermatozoa (Column 4), and based on the treatment (IVF or ICSI, columns 6 & 7). Regardless of female partner's age, the combined IVF & ICSI pregnancy rates (column 9) as well as the ICSI pregnancy rates (column 10) were numerically higher when the male partner had <10% SPTRX3-positive spermatozoa.

1	2	3	4	5	6	7	8	9	10
<i>Female age</i>	<i>Avg. male age</i>	<i>Avg. % M3 SPTRX3</i>	<i>Threshold % M3 SPTRX</i>	<i>n</i>	<i>Treated by IVF</i>	<i>Treated by ICSI (%)</i>	<i>Mature oocytes total (per couple)</i>	<i>Pregnant couples IVF & ICSI (%)</i>	<i>Pregnant ICSI couples</i>
<i>35 years or younger</i> <i>n=140</i>	33.2±0.36	14.3±0.75	<10	48	30**	21 (43%)	693 (14.1)	18/48 (38%)	9/21 (43%)
			>10	93	35***	60 (65%)	1193 (12.8)	23/93 (25%)	18/60 (30%)
<i>Older than 35</i> <i>n=99</i>	40.7±0.6	14.4±0.83	<10	25	20	5 (20%)	206 (8.24)	6/25 (24%)	2/5 (40%)
			>10	74	30****	45 (61%)	673 (9.1)	13/74 (18%)	7/45 (16%)
<p>*Age information was not provided for one female patient **Three couples were first treated by IVF before ICSI ***Three couples were first treated by IVF before ICSI ****One couple was first treated by IVF before ICSI</p>									

TABLE S7: Analysis of subgroups divided by indication (male or female infertility) and female age. Combined and idiopathic cases were not included in analysis.

A. Female infertility couples									
Age female	Avg. % M3	Avg. Male age	% M3	n	Treated by IVF	Treated by ICSI (%)	Mature oocytes total (per couple)	Pregnant couples IVF & ICSI (%)	Pregnant ICSI couples
35 yr or less	10.5±0.8	41.0 ±1.0	<10	24	23	1 (4.3%)	326 (13.6)	7 (30.4%)	0 (0%)
			>10	22	17	5 (22.7%)	278 (12.6)	7 (31.8%)	2 (40%)
>35 yr	12.5±1.2	32.8±0.6	<10	12	11	1 (8.3%)	93 (7.8)	4 (33.3%)	1 (100%)
			>10	27	19	8 (29.6%)	213 (7.9)	10 (37.0%)	1 (12.5%)
B. Male infertility couples									
Age female	Avg. % M3	Avg. Male age	% M3	n	Treated by IVF	Treated by ICSI (%)	Mature oocytes total (per couple)	Pregnant couples IVF & ICSI (%)	Pregnant ICSI couples
35 yr or less	18.3±1.6	33.4±0.7	<10	9	0*	9 (100%)	131 (14.6)	2 (22.2%)	2 (22.2%)
			>10	37	0**	37 (100%)	448 (12.1)	4 (10.8%)	4 (10.8%)
>35 yr	19.4±1.7	41.0±1.0	<10	0	0	0 (0%)	0 (0)	0 (0%)	0 (0%)
			>10	26	2	24 (92.3%)	239 (9.2)	8 (30.8%)	7 (29.2%)
*Two couples were first treated by IVF before ICSI									
**One couple was first treated by IVF before ICSI									

TABLE S8: Correlations between flow cytometric SPTRX3 values and clinical semen parameters. R-values by Person's correlation analysis are shown. Most significant values are printed bold. In general, SPTRX3 values correlate negatively with sperm count, motility, and percentage of morphologically normal spermatozoa in samples, assessed by conventional light microscopic semen evaluation. Ratio of spermatozoa to debris (%TOTAL) correlates positively with sperm count, motility and normal morphology. Bold font indicates highest correlation coefficients.

Sorted by		Clinical Parameter	Correlation with %M3	Correlation with %TOTAL	Correlation with GeoMean M3
A-None	All patients n=239	Sperm count	-0.37	0.58	-0.55
		% live sperm.	0.30	-0.19	0.23
		% prog. motile sperm.	-0.42	0.34	-0.42
		% total motile sperm.	-0.43	0.45	-0.46
		% normal sperm.	-0.35	0.30	-0.33
B-Indication:	Male infertility n=72	Sperm count	-0.24	0.38	0.28
		% live sperm.	-0.09	-0.30	-0.26
		% prog. motile sperm.	0.19	0.29	0.20
		% total motile sperm.	0.18	0.24	0.09
		% normal sperm.	-0.04	0.20	-0.06
	Female infertility n=85	Sperm count	-0.17	0.46	-0.38
		% live sperm.	0.08	-0.07	-0.02
		% prog. motile sperm.	-0.15	0.19	-0.19
		% total motile sperm.	-0.14	0.24	-0.19
		% normal sperm.	-0.17	0.32	-0.21
	Combined infertility n=61	Sperm count	0.02	0.80	-0.46
		% live sperm.	0.04	-0.35	0.45
		% prog. motile sperm.	0.01	0.39	-0.42
		% total motile sperm.	-0.17	0.39	-0.63
		% normal sperm.	-0.21	0.02	-0.13
	Idiopathic infertility n=21	Sperm count	0.35	0.19	-0.10
% live sperm.		-0.07	-0.18	-0.11	
% prog. motile sperm.		-0.02	0.25	0.27	
% total motile sperm.		-0.05	0.27	0.34	
% normal sperm.		0.23	0.04	-0.04	
C-Pregnancy	Pregnant n=60	Sperm count	-0.31	0.25	-0.22
		% live sperm.	0.09	-0.24	0.27
		% prog. motile sperm.	-0.30	0.48	-0.44
		% total motile sperm.	-0.32	0.46	-0.42
		% normal sperm.	-0.29	0.33	-0.29
	Non-pregnant n=179	Sperm count	-0.32	0.09	-0.06
		% live sperm.	0.31	-0.23	0.22
		% prog. motile sperm.	-0.36	0.26	-0.23
		% total motile sperm.	-0.38	0.30	-0.26
		% normal sperm.	-0.32	0.19	-0.10
D-Pregnancy and clinical indication	Female-pregnant	Sperm count	-0.26	0.64	-0.53
		% live sperm.	-0.06	-0.15	0.08
		% prog. motile sperm.	-0.24	0.25	-0.31
		% total motile sperm.	-0.28	0.26	-0.40
		% normal sperm.	-0.29	0.55	-0.48
	Female non-pregnant	Sperm count	-0.13	0.40	-0.34
		% live sperm.	0.14	-0.04	-0.07
		% prog. motile sperm.	-0.08	0.15	-0.12
		% total motile sperm.	-0.01	0.21	-0.06
		% normal sperm.	-0.09	0.22	-0.11

	Combined pregnant	Sperm count	0.64	0.72	-0.52
		% live sperm.	-0.22	-0.37	0.22
		% prog. motile sperm.	0.05	0.18	-0.92
		% total motile sperm.	0.22	0.36	-0.87
	Combined non-pregnant	% normal sperm.	-0.37	-0.26	-0.22
		Sperm count	-0.13	0.85	-0.54
		% live sperm.	0.12	-0.50	0.59
		% prog. motile sperm.	0.01	0.60	-0.39
	Male-pregnant	% total motile sperm.	-0.28	0.55	-0.60
		% normal sperm.	-0.21	0.18	-0.14
		Sperm count	-0.32	0.45	-0.37
		% live sperm.	0.21	0.45	0.01
	Male-non-pregnant	% prog. motile sperm.	-0.27	-0.28	0.05
		% total motile sperm.	-0.24	-0.23	0.16
		% normal sperm.	-0.22	-0.30	0.20
		Sperm count	-0.24	0.47	-0.42
	Idiopathic-pregnant	% live sperm.	0.32	-0.26	0.08
		% prog. motile sperm.	-0.35	0.02	-0.21
		% total motile sperm.	-0.27	0.16	-0.08
		% normal sperm.	-0.14	0.06	-0.14
Idiopathic-non-pregnant	Sperm count	-0.50	0.20	-0.67	
	% live sperm.	0.04	0.14	-0.45	
	% prog. motile sperm.	-0.63	0.22	-0.27	
	% total motile sperm.	-0.57	0.26	-0.32	
Idiopathic-non-pregnant	% normal sperm.	-0.57	0.12	-0.15	
	Sperm count	-0.29	0.50	-0.52	
	% live sperm.	0.26	-0.05	0.24	
	% prog. motile sperm.	-0.25	-0.02	-0.08	
E-Treatment	IVF n=98	% total motile sperm.	-0.25	0.20	-0.27
		% normal sperm.	-0.15	0.01	-0.04
		Sperm count	-0.20	0.46	-0.34
		% live sperm.	0.04	-0.03	-0.04
		% prog. motile sperm.	-0.14	0.04	-0.05
	ICSI n=131	% total motile sperm.	-0.14	0.21	-0.08
		% normal sperm.	-0.17	0.16	-0.12
		Sperm count	-0.32	0.51	-0.52
		% live sperm.	0.31	-0.10	0.19
		% prog. motile sperm.	-0.36	0.23	-0.34
		-0.37	0.33	-0.37	
		-0.28	0.14	-0.20	

TABLE S9: Spearman correlations between the most informative flow cytometric SPTRX3 parameters and the conventional semen parameters (the second numbers in the cells are the p-values).

	M	PR	NEC	NX	C
MeanM1	0.40 <0.0001	0.39 <0.0001	-0.24 <0.0001	0.27 <0.0001	0.32 <0.0001
MedianM1	0.37 <0.0001	0.36 <0.0001	-0.23 0.0004	0.24 0.0002	0.26 <0.0001
CVM1	-0.35 <0.0001	-0.35 <0.0001	0.24 <0.0001	-0.23 0.0002	-0.28 <0.0001
%M2	0.50 <0.0001	0.48 <0.0001	-0.34 <0.0001	0.36 <0.0001	0.48 <0.0001
%M3	-0.45 <0.0001	-0.43 <0.0001	0.31 <0.0001	-0.32 <0.0001	-0.41 <0.0001

Abbreviations:

C=sperm count

V=semen volume

M=total motility

PR=progressive motility

NX=morphology/ % normal spermatozoa

NEC=percent of necrotic spermatozoa assessed by Williams test

TABLE S10: Conventional semen parameters for semen samples used for Western blotting.

SAMPLE NUMBER	PRESUMED FERTILE DONORS			DIAGNOSED, TERATOSPERMIC MALE INFERTILITY PATIENTS		
	1	2	3	4	5	6
SPERM COUNT (x10 ⁶)	117	143	205	18	54	44
% MOTILE	60	70	65	0.2	0.9	20
% MORPHOL. DEFECTS	28	22	26	97	98	87
AGE	20	27	23	26	33	34
SPTRX3/TUBB RATIO	1.34	0.26	0.23	0.85	0.98	1.42

Supplemental Statistical Information (Discriminant Function Analysis)

ANALYSIS I: Discriminant analysis using SAS PROC discrim and stepdisc procedures was applied to study the relationship of pregnancy rate with the sperm quality parameters and SPTRX3 levels, with consideration of treatment assignments.

SAS *proc discrim* procedure was applied to conduct discriminant analysis to understand the relationship between the pregnancy rate and all the sperm quality parameters. When all data is considered and all sperm quality parameters are considered, there is no significant discriminant function. The stepwise discriminant analysis identifies one significant predictor, PR, which leads to a discriminant function with canonical correlation of 0.13 (p-value=0.05). The cross-validated classification accuracy rate based on this discriminant function is 75%. The PR variable separates the two groups well with mean value of 21.6 for the non-pregnant group and 24.8 for the pregnant group.

When considering the IVF group only, no significant discriminant function is detected when all sperm quality parameters are considered. The stepwise discriminant analysis identifies Volume and M2% as significant predictors and the discriminant function based on these two variables is significant with p-value=0.008 and has canonical correlation of 0.3. The discriminant function is highly positively correlated with M2% ($r=0.71$) and negatively correlated with Volume ($r=-0.68$). The cross-validated classification accuracy rate of this discriminant function is 73%. The means of M2% are 81.4 versus 84.2 for non-pregnancy group and pregnant group, respectively. The volume has mean 3.4 for non-pregnancy group and 2.8 for pregnancy group.

When considering the ICSI treatment group only, the *stepdisc* procedure identified four predictors: V, PR, M and C. The discriminant function based on these four predictors has p-value=0.014 and canonical correlation of 0.31. The cross-validated classification accurate rate is 78%. The structure matrix shows that this discriminant function is positively correlated with C ($r=0.52$) and negatively correlated with V ($r=-0.5$). The C variable separates the two groups well with 44.9 (non-pregnancy group) versus 26.7 (pregnancy group). The V variable has mean of 3.1 (no pregnancy) versus 3.6 (pregnancy).

If only the biomarker parameters are considered, the discriminant analysis identified %M2 and CVM3 as significant predictors for the IVF group (**Table S11**). The discriminant function has p-value 0.025 with canonical correlation of 0.26. It has positive correlation with %M2 ($r=0.82$) and CVM3 ($r=0.77$). The cross validated classification accuracy rate is 72% and the two variables %M2 and CVM3 separates the pregnancy group from the no-pregnancy group well.

If only the biomarker parameters are considered, the discriminant analysis identified Median M3 as a significant predictor for the ISCI group. The discriminant function has p-value 0.05 with canonical correlation of 0.17. The cross validated classification accuracy rate is 80% and the variable Median M3 separates the pregnancy group from the no-pregnancy group well with means of 232 versus 212 for the two groups.

TABLE S11:

Pregnancy	Obs	Variable	N	Mean	Std Dev	Minimum	Maximum
YES	75	%M2	75	81.43	6.33	47.92	89.43
		CVM3	75	156.85	27.76	89.42	230.44
NO	32	%M2	32	84.18	4.03	72.95	89.42
		CVM3	32	169.81	31.11	98.96	258.01

ANALYSIS II: *Discriminant analysis was conducted to study the relationship of the treatment assignment, SPTRX3 and the sperm quality parameters. SAS proc discrim procedure was used to conduct discriminant analysis to study the relationship between the treatment assignment and the sperm quality parameters.*

The discriminant function is highly significant ($p < 0.0001$) with canonical correlation of 0.67. The structure matrix in **TABLE S12** shows that the discriminant function is positively correlated with PR (0.78), C (0.62), M (0.59) NX (0.54), % Total (0.48), %M2% (0.43) and negatively correlated with Mean M3 (-0.5), Median M3 (-0.43), NX (% normal sperm) (-0.39) and %M3 (-0.37). The cross-validated classification accuracy rate based on this discriminant function is 80%. Note that the above 10 predictors include the same nine predictors in the analysis of male infertility indicators besides the NX variable.

TABLE S12: Pooled Within Canonical Structure

Variable	Can1
M1	-0.041339
M2	0.431106
M3	-0.369862
Total	0.478822
Meanall	-0.259177
MeanM1	0.294226
MeanM2	-0.067757
MeanM3	-0.503966
CVall	-0.226949
CVM1	-0.251488
CVM2	-0.143186
CVM3	-0.134124
MedianALL	-0.197052
MedianM1	0.226282
MedianM2	-0.080284
MedianM3	-0.432187
V	0.023715
C	0.616992
NEC	-0.390293
M	0.588741
PR	0.779281
NX	0.544063

Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; NX=morphology/ % normal spermatozoa; NEC=percent of necrotic spermatozoa assessed by Williams test

TABLE S13 gives the means of the ten variables by the treatment groups and shows that the ten variables separate the two groups well. For instance, %M2 has a mean of 82.25 for the IVF group and a mean of 76.41 for the ICSI group.

Table S13:

<i>Treatment</i>	<i>Obs</i>	<i>Variable</i>	<i>Mean</i>	<i>N</i>
IVF	107	%M2	82.2496262	107
		%M3	11.3400935	107
		Total	89.8795327	107
		MeanM3	229.6221495	107
		MedianM3	184.2907477	107
		C	95.7102804	107
		NX	24.4439252	107
		M	47.5981308	107
		PR	29.2523364	107
		NX	49.8773585	106
ICSI	131	%M2	76.4079389	131
		%M3	16.8411450	131
		Total	80.2452672	131
		MeanM3	274.9711450	131
		MedianM3	215.6846565	131
		C	41.1854962	131
		NX	32.1267717	127
		M	34.6564885	131
		PR	16.5590551	127
		NX	34.1111111	126

Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; NX=morphology/ % normal spermatozoa; NEC=percent of necrotic spermatozoa assessed by Williams test

ANALYSIS III: Logistic regression analysis using SAS proclogistic procedure was applied to study the relationship of pregnancy rate with the sperm quality parameters with consideration of female age and treatment assignments.

Considering only the patients assigned to the IVF treatment, both %M2 SPTRX3 and %M3 SPTRX3 were significant predictors for pregnancy rate, with or without adjustment for the female age factor. None of the convention parameters or other flow cytometric parameters was significant even with adjustment for the female age. The odds of getting pregnant in the IVF group were reduced by 10.2% for every unit of increase in %M3 (p-value=0.03). After adjusting for the factor of female partner's age (35 years or younger vs. older than 35), the odds of getting pregnant in the IVF group were reduced by 11.1% for every unit of increase in %M3 (p-value=0.03). The odds of getting pregnant when %M3 was below 5% were 6.7 times better than for the %M3 levels above 15% (p-value=0.05). After adjusting for female age, the adjusted odds ratio was 7.5 with p-value=0.04. We found that %M2 was also a significant predictor for pregnancy rate for IVF group with p-value=0.03 and the odds ratio is 1.1 for each unit increase. After adjusting for the female age, the p-value=0.02 and the odds ratio was 1.1 (i.e. the odds of getting pregnant in IVF group increased by 13.6% for every unit increase of %M2).

For the ICSI group, the pregnancy rate was not affected by any of the new or conventional sperm quality parameters or the female age factors. When considering all patients together, %M3 and %M2 were not significant predictors for pregnancy rate (p-value=0.38 and 0.50 respectively). However, when we considered categorizing the %M3 levels into four groups, below 5%, between 5-10%, between 10-15%, and above 15% SPTRX3-positive spermatozoa, the estimated odds ratio between the below 5% group and the above 15% group was 2.94 with p-value=0.06. In other words, the odds of getting pregnant when the SPTX3 levels was below 5% were 2.94 times better than that for the SPTX3 levels above 15%. After adjusting for female age, the adjusted odds ratio for the below 5% SPTX3 group over the above15% SPTX3 group was 3.3 with p-value=0.04. Using 85% as a cutoff for %M2, the below 85% group and above 85% group had significantly different pregnancy rate when considering all patients together. The odds of getting pregnant for the above 85% of %M2 group were 113.2% better than that for the below 85% group (p-value=0.02) and the pregnancy rate was 41.5% versus 22.72%. After the adjustment for the female age, the odds ratio was 2.1 with p-value=0.02.

ANALYSIS IV: Discriminant analysis using SAS proc discrim procedure was conducted to explore the relationships between the clinically diagnosed male infertility and sperm quality parameters. Both male-only and combined (female & male) infertility cases are considered to be male infertile cases in this analysis of various sperm quality measurements including the conventional parameters and the parameters based on SPTRX3 analysis by flow cytometry.

SAS *proc discrim* procedure was used to study the relationship between the male infertility indicator variable and all the sperm quality parameters. The discriminant function detected is highly significant with $p\text{-value} < 0.0001$ and has the canonical correlation of 0.83, which is the maximal multiple correlation of the linear combination of the sperm quality parameters with the male infertility indicator variable. **TABLE S14** (below) presents the canonical structure matrix of the discriminant analysis, which shows that the discriminant function is positively correlated with progressive motility (PR; $r=0.84$), total motility (M; $r=0.60$) and % normal spermatozoa (NX; $r=0.46$), C ($r=0.46$), % Total ($r=0.35$), %M2 ($r=0.33$) and negatively correlated with %M3 ($r=-0.29$) Mean M3($r=-0.35$) and Median M3($r=-0.30$). The cross-validated classification accuracy rate based on the discriminant function is 90%. **TABLE S15** shows means of the above nine variables separately for infertile and fertile male. Based on Table 13, all nine variables (PR, M, NX, C, % Total, % M2, % M%, Mean M3 and Median M3) clearly separate the two groups. For example, PR separates the two groups with a mean of 11.5 for infertile male and 29 for fertile male. %M3 has mean 18.6 for infertile group versus mean 11.6 for the fertile group, which is in accordance with the proposed property of SPTRX3 protein as a biomarker specific to defective spermatozoa associated with male infertility.

TABLE S14: Canonical structure matrix of the discriminant analysis of the relationship between male infertility and sperm quality.

Pooled Within Canonical Structure

<i>Variable</i>	<i>Can1</i>
M1	0.005240
M2	0.327101
M3	-0.294292
Total	0.345735
MeanAll	-0.231519
MeanM1	0.215277

MeanM2	-0.118957
MeanM3	-0.349959
CVall	-0.151343
CVM1	-0.186697
CVM2	-0.024542
CVM3	-0.100571
MedianALL	-0.192479
MedianM1	0.210773
MedianM2	-0.126937
MedianM3	-0.299451
V	0.021139
C	0.456325
NEC	-0.244176
M	0.601372
PR	0.841907
NX	0.458204

TABLE S15: Means of the nine variables for infertile male and fertile male

Mean	Infertile male	Fertile male
PR	11.5	29
M	29.3	47.6
NX	28.6	49.1
C	27.2	90.3
% Total	77.8	88.9
M2% SPTRX3	78.8	81.8
M3% SPTRX3	18.6	11.6
MeanM3 SPTRX3	285.5	234.7
MedianM3 SPTRX3	223.1	187.7
Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; NX=morphology/% normal spermatozoa		